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Aim at perfection in everything, though in most things it is 
unattainable. However, they who aim at it, and persevere, will 
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Recent publications have repeatedly highlighted the unreliability of academic 
research when translated to industry. This subject has been debated in publications 
such as Nature Drug Discovery, RQA monthly, Life Sci VC and Lab Times with many 
reasons cited including research bias, academic self-interest, apathy, pressure to 
publish and “massaging data to fit the hypothesis”. 1 5 
Resistance in colon and pancreatic cancer is well documented but the literature is 
conflicted. Perhaps this is because of biological variability but it could be due to 
experimental design. The aim of this project is to conduct a study, mindful at each 
stage of how quality management might inform the interpretation of findings 
Colorectal cancer is the third most common cancer for both males and females in the 
UK and makes up 13% of all cancers.2  5-fluorouracil (5-FU) has been, and remains, 
the first line drug of choice for treating colorectal cancer, both as a monotherapy and 
in combination with other drugs.  However, the response rate is around 20% when 
used singly and just under 50% when used in combination.3 11 113 
Pancreatic cancer is the tenth most common cancer in the UK and makes up 2.55% 
of all cancers.  The average survival time for a pancreatic cancer patient following 
surgical resection is approximately 11-20 months.  This drops to 6-11 months in 
unresectable localised tumour patients.  For patients with unresectable, metastatic 
disease the average survival time is 2-6 months.   
Although 5-FU and gemcitabine remain the first line treatment for colorectal and 
pancreatic cancers, there are no definitive markers of resistance which may be used 
to predict response to these drugs. 
Investigation into prognostic and predictive biomarkers based upon putative 
resistance to these drugs is crucial to tailor therapy in patients with a potentially very 
limited lifespan. Automated quantitative analysis (AQUA) is a novel image analysis 
system of quantifying protein expression levels, including potential biomarkers, in 
cells. 
This thesis addresses the hypothesis that quantitative expression of protein 
expression can be used to identify putative biomarkers of gemcitabine resistance in 
pancreatic cancer, and that the methodology is transferrable to other disease types.  
Using pancreatic cancer as the lead disease this project aims to measure the 
expression levels of proteins critical for both pathways – thymidylate synthetase (TS), 
ribonucleotide reductase subunit M1 (RRM1), ribonucleotide reductase subunit M2 
(RRM2), cytidine deaminase (CDA), human equilibrative nucleoside transporter 1 
V 
(hENT1) - and pathway specific proteins – dihydropyrimidine dehydrogenase (DPYD) 
and thymidine phosphorylase (TP) for 5-FU- and a gemcitabine pathway-specific 
protein, deoxycytidine kinase (DCK). Thereafter, in a briefer study, the application of 
the approach to colorectal cancer was investigated. 
Archival FFPE blocks were used to construct tissue microarrays (TMAs) in 
quadruplicate and patient demographics were collated.  An antibody validation 
algorithm was formulated to authenticate antibodies prior to use.  A quality 
programme was initiated and maintained throughout the length of the project to 
ensure data integrity and reproducibility of results.  The expression levels of the 
proteins were quantified using Automated QUantitative Analysis (AQUA). 
Low CDA and RRM1 expression were associated with longer disease free survival in 
all patients.  Medium CDA expression was associated with longer overall survival in 
the patients who did not receive any chemotherapy.  Low RRM1 expression was 
linked with longer overall and disease free survival in the gemcitabine cohort. 
Multivariate analysis showed that a high Lecca value was linked to increased survival 
time, statistically significant in the gemcitabine group – p = 0.007 for overall survival 
and p = 0.07 for disease free survival. 
24% of patients who received no chemotherapy (high expression group) were still 
alive at 48 months and 25% of patients who received gemcitabine (high expression 
group) were still alive at 72 months. 
In the low expression groups, both sets of patients had the same amount of time to 



















Colorectal cancer is the third most common cancer for both males and females in the 
UK and makes up 13% of all cancers. 5-fluorouracil (5-FU) has been, and remains, 
the first line drug of choice for treating colorectal cancer, used on its own as well as 
in combination with other drugs.  However, the response rate is around 20% when 
used singly and just under 50% when used with other drugs. 
Pancreatic cancer is the tenth most common cancer in the UK and makes up 2.55% 
of all cancers.  The average survival time for a pancreatic cancer patient following 
surgery to remove the tumour is approximately 11-20 months.  This drops to 6-11 
months in patients with tumour that is only located in the pancreas and cannot be 
removed by surgery.  For patients with tumour that has spread to other parts of the 
body the average survival time is 2-6 months.  Gemcitabine is the first line drug of 
choice to treat pancreatic cancer. 
Resistance of colorectal and pancreatic cancer is well documented but reasons 
reported contradict one another.  This could be due to variations in the tumours but 
also could be due to lack of quality control measures. This project was conducted 
with a quality programme implemented to try and work out what causes resistance 
or response to 5-FU and gemcitabine by looking at substances expressed or 
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1. Introduction and background 
1.1 The quality of academic research 
There have been many recent reports on the quality, or lack of it, of academic 
research. The irreproducibility of academic research has been highlighted in many 
articles. 1  It has been reported that at least 50% of articles published in elite 
journals cannot be reproduced by other labs. 1 5  The reasons cited for this include 
research bias and academic self-interest. 5  Researchers have a clear vision of what 
they expect from their research and, either consciously or unconsciously, design the 
methodology and statistical analysis to produce expected results.  Researchers are 
under constant pressure to publish, in fact many post-doctoral positions are 
conditional on publishing, and typically only positive results are published.  Papers 
published in top journals facilitate future publication, which means the cycle of 
irreproducibility is perpetuated. 
Within the research rat race of academia, it often seems to be a waste of time and 
effort to apply for grant funding with a hypothesis that is in direct contradiction of 
already published articles in leading journals.  Researchers are more likely to be 
remembered for startling discoveries than disproving an existing publication.  
The reasons governing which research topics are likely to receive funding are 
interesting. 3 4 
The winner of the 2013 Nobel Prize for Medicine and Physiology – Randy W 
Schekman – publicly stated that he will boycott three top journals because “pressure 
to publish in ‘luxury’ journals encourages researchers to cut corners and pursue 
trendy fields in science instead of doing more important work.”  Dr Schekman 
maintains that research is judged by the impact factor of the journal it is published in 
and that these journals only accept papers that “will make waves because they 
explore sexy subjects or make challenging claims.”  The impact factor does not 
reflect the quality of the research and encourages fashion trends in research rather 
than promoting replication studies.4 
Perhaps the answer to this dilemma is web-based, open-access journals with no 
subscription fee which publish all papers which meet certain quality standards with 
no caveats about positive or negative results or replication studies. 4 
 
How has it come about that academic research is perceived as so fundamentally 
flawed that even publication in an elite journal cannot guarantee the quality of the 
2 
research?  It could be a series of factors that are committed, either unconsciously or 
consciously, which compounded together render research irreproducible. 
For example: 
I. Bias – how many researchers can say honestly that if they don’t get the 
expected results (which fit their hypothesis) they repeat the experiment until 
the results are as expected? 
II. Results – likewise, if the results are as expected how many researchers repeat 
the experiment to prove it wasn’t a fluke?   Are results cherry-picked to fit the 
hypothesis? 
III. Controls – how many researchers can confirm that they always use appropriate 
positive and negative controls? 
IV. Reagents – all reagents used must be validated.  This is reflected in the fact 
that analytical grade chemicals from reputable suppliers are used in 
laboratories.  Antibodies, however, are a different matter.  The onus is on the 
researcher to validate the antibody they are using.  How many researchers take 
the time to validate the antibodies they are using? 
How many generic emails are circulated round academic mailing lists begging 
for a vial of a particular cell line when it is next being split or a few microlitres of 
a particular antibody that will be replaced when their order arrives?  How 
reliable would these be in a research study – there is no provenance - and how 
are they written into a publication? 
 
To add to the above points, pressure is put on junior researchers to produce “good 
results”. 4 5  The Principal Investigator (PI) is not interested how these results were 
obtained, only that they are as expected.  This puts enormous pressure on junior 
researchers to produce expected results by any means possible. 
Booth also comments on the quality of the Material and Methods section of scientific 
publications and the reluctance of researchers to fully disclose how the experiments 
were done and using exactly which reagents.5 
He reiterates the point made above that states that only the “best results” are used 
and contradictory data is ignored. 
 
What is quality?   
It is defined in the Oxford Dictionary as “the standard of something as measured 




Waddell further divides “quality” into:   
a) Quality control (QC) – this is quantitative and can be applied throughout the 
study by the researcher and any other study personnel. 
b) Quality assurance (QA) – this is qualitative and should be conducted pre, 
during and post research by independent, appropriately qualified QA 
personnel. 6                    
 
This thesis addresses the hypothesis that quantitative expression of protein 
expression can be used to identify putative biomarkers of gemcitabine and 5-FU 
resistance in pancreatic and colorectal cancers, and that the methodology is 
transferrable to other disease types.  
 
Aim of the study 
The aim of this study is to analyse a range of biomarkers which may be associated 
with gemcitabine and 5-FU resistance.  The results of this study could have major 
implications for the patient population if it were found that one or several of these 
biomarkers were clinically relevant to survival time and/or resistance.  At best, 
patients’ survival could be prolonged; at worst, patients would not be subjected to 
the debilitating side-effects of chemotherapeutic drugs. 
With this in mind, this project used Quality Management wherever feasible to ensure 

















1.2 Biology of normal colorectal tissue 
COLON 
 
  + 
     Figure 1.1 The colon and rectum 7                           
If the large and small intestines were laid out in a straight line they would measure 
around 7m in a normal human adult.  The large intestine is so named because it is 
wider in diameter when compared to the small intestine. It measures 1.5m when laid 
out straight with a diameter of 7.5cm.  The small intestine is much longer – around 
7m in length – with an average diameter of 2.5cm. 8 
Normal colon consists of four basic layers: mucosa, sub mucosa, muscularis externa 
and serosa. 
The mucosa layer consists of three layers: 
1) Muscularis mucosa – consists of two thin layers of smooth muscle. 
2) Lamina propria – consists of a thin layer of loose connective tissue.  There are no 
villi but numerous tubular glands which duct on to the surface epithelium and secrete 
mucus and other serous secretions. 
3) Surface epithelium – simple columnar epithelium which contains very few goblet 
cells. 
The sub mucosa layer contains no plicae but does include lymph nodules. 
The muscularis externa layer consists of two layers: 
i) Outer longitudinal layer consisting of three bands of muscle fibres called taeniae.  
 
  Ascending 







ii) Inner circular layer, which is a thin layer of muscle. 
The serosa layer is the outermost layer and consists of areolar tissue, which is 
continuous with the mesentery supporting the gut. 
 
                        
Figure 1.2 Normal colon stained               Figure 1.3 Transverse section  
  with haematoxylin and eosin 9                                of colon 
                      
RECTUM 
The rectum is the final portion of the large intestine.  It is approximately 12cm in 
length and consists of the same four basic layers as colon: mucosa, sub mucosa, 
muscularis externa and serosa. 
The mucosa layer consists of three layers: 
1) Muscularis mucosa – consists of two thin layers of well-developed smooth muscle.  
Lamina propria and sub mucosa merge in the rectum. 
2) Lamina propria – consists of a thin layer of loose connective tissue which is much 
thicker than in the colon. 
3) Surface epithelium – this becomes stratified squamous towards the recto-anal 
junction where it becomes longitudinal folds called columns of Morgagni. 
The sub mucosa layer contains few lymph nodules.  In the anal canal there is a good 
supply of small veins which can dilate and bulge into the lumen – haemorrhoids. 
 
The muscularis externa layer consists of two layers. 
1) Outer longitudinal layer with no taeniae.  
2) Inner circular layer, which is a thin layer of muscle. 







The serosa layer is the outermost layer and consists of areolar tissue which is 
continuous with the mesentery supporting the gut. 
 
 
     
 
Figure 1.4 Normal rectum stained with haematoxylin and eosin (x10 and x20) 10         
  
Malignancy 
Malignant is defined in the Oxford English Dictionary as “… (of a neoplasm): having 
the property of uncontrolled growth, with loss of differentiation, invasion and 
destruction of local tissue, and (often) metastasis to distant sites. Also: of the nature 
of or caused by such a neoplasm.”   
In order to appreciate and understand malignancy it is necessary to study and be 
cognizant of the structure and function of normal tissues and organs.   
 
1.2.1 Colorectal cancer 
Colorectal cancer is the third most common cancer for both males and females in 
Scotland (in 2012) and makes up 13% of all cancers. 
2
 
The biggest challenge faced by oncologists today is predicting which patients will 
respond to treatment.  5-fluorouracil (5-FU) is the first line treatment for colorectal 
cancer, used both singly and in combination with other drugs; however, the response 
rate is around 20% when used singly and just under 50% when used in combination. 
3 11   
 
1.2.1.1 Incidence and survival rates of colorectal cancer 
Colorectal cancer is the second most common cause of tumour-related death in the 
UK.  It is the third most common cancer in the world and accounts for 10% of all 
7 
cancers worldwide. It is the third most common cancer in both males and females in 
the UK – 13% of all cancers – accounting for 11% of all cancers.  Around 66% of 
colorectal cancers originate in the colon and around 34% originate in the rectum 
according to UK statistics.  63% of rectal cancers occur in males whereas colon 
cancer has an even male/female distribution.12 
 
     
Table 1.1 New cases and rates of colorectal cancer in the UK in 2010 13 
 
Duke’s A colorectal cancer has a 5-year relative survival rate of over 90% whereas 
for Duke’s D colorectal cancer, the 5-year relative survival rate is under 7%.  Surgical 
excision is the optimal treatment for non-metastatic patients whilst surgical resection 
and adjuvant chemotherapy is recommended for advanced stage patients. 14  
   
Duke’s stage at 
diagnosis 
 
Percentage of cases 5-year relative survival 
A 8.7% 93.2% 
B 24.2% 77.0% 
C 23.6% 47.7% 
D 9.2% 6.6% 
Unknown 34.3% 35.4% 
 
Table 1.2 Percentage of cases and 5 year relative survival (%) by Duke’s stage at 
diagnosis, colorectal cancer patients diagnosed 1996-2002, England  14 
 
The Scottish Bowel Screening Programme was implemented by all Scottish health 
boards by December 2009.  Up to 31st October 2010 in the Scottish Bowel Screening 
Programme: 
Colorectal Cancer  England Wales Scotland Northern 
Ireland 
UK 
Male Cases 18,590 1,421 2,177 646 22,834 
Female Cases 14,628 933 1,790 510 17,861 
Persons Cases 33,218 2,354 3,967 1,156 40,695 
Crude rate = incidence per 100,000 people 
Male Crude 
Rate 
72.2 96.6 86.0 73.0 74.5 
Female Crude 
Rate 
55.2 60.8 66.5 55.7 56.5 
Persons Crude 
Rate 
63.6 78.3 76.0 64.2 65.4 
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•Just fewer than 1,500,000 individuals were invited to take part 
•Over 800,000 took up the offer and achieved a final result 
•Over 1400 cancers were diagnosed through screening                                   
Therefore, approximately half of individuals invited to take part in the screening 
programme responded and of this half, approximately 3% were diagnosed with 
colorectal cancer.15  
 
1.2.1.2 Location and histological sub-types of colorectal cancers 
Colorectal cancer may be divided into categories based on the location and 
histological characteristics of the tumour.  Colon cancer can initially be divided into 
right sided and left sided.  Research has been conducted on right versus left sided 
colon cancer with the conclusion that right-sided colon cancers have less overall 
survival times than left-sided cancers. 16 17  Colon cancer can also be categorised into 
actual location of the tumour: ascending colon, descending colon, caecum, distal 
sigmoid colon, distal transverse colon, hepatic flexure, ileocaecal valve, left colonic 
phlegmon, mesorectum, mid transverse colon, proximal transverse colon, 
rectosigmoid, rectum, sigmoid colon, splenic flexure and transverse colon. 
The WHO classifies colorectal tumours as follows: 
 
Epithelial tumours Non-epithelial tumours 
Adenocarcinoma Tubular Lipoma 
 Villous Leiomyoma 
 Tubulovillous Gastrointestinal stromal 
tumours 
 Serrated Leiomyosarcoma 
Carcinoma Adenocarcinoma Angiosarcoma 
 Mucinous adenocarcinoma Kaposi sarcoma 
 Signet-ring cell carcinoma Malignant melanoma 
 Small cell carcinoma Malignant lymphoma 
 Squamous cell carcinoma  
 Adenosquamous carcinoma  
 Medullary cell carcinoma  
 Undifferentiated carcinoma  
 
Table 1.3 WHO classification of tumours of the colon and rectum 18 
 
 
Adenocarcinoma is the most common type of colorectal cancer which accounts for 
90-95% of all colorectal cancers. 
Adenocarcinomas can be either mucinous or non-mucinous.  The mucinous subtype 




1.2.1.3 Risk factors in colorectal cancer 
 
(i) Age and sex – the risk of developing colorectal cancer increases directly with 
age.  The amount of cases for males peaks between the ages of 70 and 79, before 
declining sharply in the early to late eighties. 
For females, there is a gradual increase up to age 75 after which the number of 
cases remains more or less static. 19 
 
(ii) Diet – there is increasing evidence that eating a diet rich in red and processed 
meat increases the risk of developing colorectal cancer 20 21; however there is no 
convincing evidence that fish consumption, in particular fresh or salted fish, reduces 
the risk. 22 
 
A high fibre diet, especially from cereals and whole grains, has been shown to 
protect against colorectal cancer.  No association was found with fibre from fruit and 
vegetables. 23  In fact, the risk reduction from a diet high in fruit and vegetables is 
negligible, although eating garlic – both cooked and uncooked – may be associated 
with a reduction in risk.  Evidence is unclear as garlic is very rarely eaten as a single 
food item, therefore it could be the reduction in risk only occurs when consumed with 
other vegetables or herbs.  There has been no benefit seen from garlic supplements. 
24 
There is no conclusive association between a high fat diet and colorectal cancer. 21 
An increased daily intake of milk reduces the risk of colorectal cancer. It is thought 
that the effect from milk is likely to be related to calcium. 25 
Any evidence that high sugar consumption is a risk factor is very limited.  26 
 
(iii) Obesity – the risk of colorectal cancer increases with BMI, or more specifically 
waist size.  The risk is greater in men than women. 27 28 
 
(iv) Exercise – the risk of colon cancer reduces as one exercises but the risk for 
rectal cancer does not change. 29 30 
 
(v) Alcohol and smoking – moderate alcohol consumption increases the risk of 
colorectal cancer, the risk increasing directly proportionally to alcohol intake. 
A moderate amount of alcohol is anything more than a small glass of wine or half a 
pint of beer per day. 31 
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The risk of colorectal cancer increases with the number of cigarettes smoked per day. 
Ex-smokers are at greater risk than people who have never smoked.  Smoking 
increases the risk of developing rectal cancer more than colon cancer. 32 
 
(vi) Nonsteroidal anti-inflammatory drugs – low dose aspirin (75mg/day) has 
been shown to significantly reduce the risk of colorectal cancer. 33 
 
(vii) Statins – the evidence on statin use remains unclear however, a recent study 
showed that using statins for 4 years or more increased the risk of colorectal  
cancer. 34 
 
(viii) Hormone replacement therapy (HRT)/oral contraceptives (OC) – the 
evidence is mixed for HRT however risk is reduced for women who have ever taken 
OCs, the risk reduction being greater the more recent the use. 35 
 
(ix) Inflammatory bowel disease – the risk of developing colorectal cancer is 
increased in people with ulcerative colitis and Crohn’s disease, the risk increasing 
with the years of suffering the disease. 36 
 
(x) Diabetes – research has shown an increased risk in people with type II diabetes 
patients.  However, metformin is associated with a decrease in risk. 37 38 
 
(xi) Human papilloma virus (HPV) – approximately 90% of invasive anal cancers 
are linked to HPV infection, with HPV16 being the most common type. 39 
 
(xii) Radiation – more than 1% of all colorectal cancers in the UK can be linked to 
radiation exposure. 40 
 
(xiii) Family history – hereditary factors account for around 20% of colorectal 
cancers with a direct 5% attributed to familial adenomatous polyposis (FAP), 
polyposis syndromes and hereditary non-polyposis colorectal cancer (HNPCC).  
Although patients with FAP have almost 100% risk of developing colorectal cancer by 
the age of 40, this population accounts for less than 1% of all colorectal cancers. 41 
Patients with HNPCC account for 1-4% of all colorectal cancers.  
Other hereditary factors account for another 5% of colorectal cancers. 42 
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1.2.1.4 Diagnosis of colorectal cancer 
The diagnosis of any cancer is predominantly as a result of a patient presenting to 
their GP with a symptom or symptoms that are not a feature of their everyday life. 
As previously stated, the Scottish Bowel Cancer Screening Programme identifies that 
3% of all persons screened will be diagnosed with colorectal cancer. For those who 
are too young or decline to take part in the screening programme, there will be 
symptoms of the disease that lead to a diagnosis being made. 
The symptoms of colorectal cancer are: 43 
 Rectal bleeding 
 Abdominal pain 
 Altered bowel habits 
 Anaemia 
 Weight loss 
 Anorexia 
 Fatigue 
 Nausea or vomiting 
 Tenesmus 
 Mucous in stools 
 Rectal pain 
 Obstruction 
If colorectal cancer is suspected then a variety of methods are utilised to investigate: 
1) Digital rectal examination – this is usually performed by the GP to ascertain 
whether there is a palpable lump within the rectum. 
2) Colonoscopy – a colonoscope is inserted into the rectum and manoeuvred 
throughout the length of the colon.  A small camera and light are attached to the end 
of the colonoscope which means images can be taken.  A small biopsy sample may 
also be taken during this procedure. 
3) Sigmoidoscopy – this is identical to a colonoscopy except that the tube inserted is 
much shorter and can only be used to examine the rectum and part of the colon. 
4) Computerised Tomography/Magnetic Resonance Imaging (CT/MRI) scans – these 
scans are used to give a detailed depiction of the colorectal area.  They may also be 
used to determine if there are any metastases in other organs. 
 
1.2.1.5 Staging of colorectal cancers 
Colorectal cancer is staged using the TNM system and also the Duke’s classification. 
12 
As with all cancers, staging is used to describe the extent and severity of disease and 
may facilitate treatment plans and indicate the prognosis of the patient. 
The TNM system looks at the size of the primary tumour (T), whether there is 
evidence of cancer cells in the lymph nodes (N) and whether the cancer has spread 
to other parts of the body (M).  Duke’s staging is used only for colorectal cancer and 
compares with the TNM system as shown in the table below. 
Stage T N M Duke’s classification 
I 
T1 N0 M0 A 
T2 N0 M0 B1 
II 
T3 N0 M0 B2 
T4 N0 M0 B2 
III 
T1, T2 N1, N2 M0 C1 
T3, T4 N1, N2 M0 C2 
IV Any Any M1 D 
 
Table 1.4 Comparison of TNM staging with Duke’s classification 44 45 
 
See Appendix 1 for staging and grading of colorectal tumours. 
 
1.2.1.6 Treatment of colorectal cancer 
Once a diagnosis has been confirmed, treatment options are determined by the 
stage, grade and location of the tumour, the patient’s age and general health.  Other 
factors that will influence treatment are the biological and genetic properties of the 
cancer cells. 
The options available are surgery, radiotherapy and chemotherapy; often a 
combination of all three. 
Surgery 
In early stage cancers surgical resection is a method used to potentially remove the 
entire tumour.  This can be ameliorated by pre-surgery radiotherapy to shrink the 
tumour and post-operative chemotherapy to treat any potential cells left in situ. 
The most important factor in this type of surgery is the distance between the 
resection margin and the tumour and the presence/absence of any residual tumour. 
Radiotherapy 
Often used for rectal tumours both pre- and post-surgery and given in combination 
with chemotherapy to either reduce tumour size pre-surgery or treat any remaining 
cancer cells post-surgery. 
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Chemotherapy 
The standard chemotherapy first-line treatment for colorectal cancer is 5-fluorouracil 
(5-FU).  This is despite the fact that the response rate is less than 20% when used as 
a monotherapy.  The response rate rises to 20-30% when leucovorin (folinic acid) is 
administered at the same time.  When oxaliplatin is added to the treatment the 
response rate increases to just less than 50%.  5-FU may also be given in 
combination with irinotecan. 
3
 
Capecitabine is a prodrug which may be given orally, and is converted to 5-FU within 
the tumour cells.  5-FU is delivered intravenously. 
Adjuvant chemotherapy may be offered to patients depending on the stage of the 
disease and the success of the resection.  The most common drugs used are: 
 FOLFOX – a combination of folinic acid, 5-fluorouracil and oxaliplatin given 
intravenously 
 Capecitabine – given orally 
 Fluorouracil (5-FU) as a monotherapy – given intravenously 
 XELOX  or CAPOX – a combination of oxaliplatin and capecitabine 46 
 
1.2.1.7 Metastasis of colorectal cancer 
Fewer than 25% of people who develop colorectal cancer will ultimately have 
metastasis to the liver.  As the liver metastases rather than the primary tumour 
determine the prognosis of the patient, it is important to check the concurrence of 
protein expression in both tumour sites. 47 Research has shown that although the 
primary tumour may respond to chemotherapy, the metastatic tumour is more 
resistant. 48  The proteins associated with the metabolism of 5-FU are thymidine 
phosphorylase, dihydropyrimidine dehydrogenase, ribonucleotide reductase subunit 


























Figure 1.5 The site of the pancreas within the body showing the proximity to other 
organs 49 
 
The pancreas is located just behind the stomach.  The head of the pancreas nestles 
in the curve of the duodenum, the body of the pancreas lies in close proximity to the 
liver and the tail of the pancreas is closest to the spleen.  The uncinate process is the 
part of the pancreas that bends backwards and underneath itself. 
The pancreas is approximately 6 inches long and shaped like a flattened pear. 
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Body of pancreas 

















The pancreatic duct runs the length of the pancreas with many smaller ducts 
branching off.  The pancreatic duct merges with the common bile duct at the 
entrance to the duodenum to form the ampulla of Vater. 
 
The pancreas has two distinct components with their own unique function, the 
endocrine and exocrine parts.  The endocrine substances produced are secreted 
directly into the bloodstream. 
The exocrine part of the pancreas contains glands which produce digestive enzymes.  
It contains two major types of cells: 
Acinar cells – these produce digestive enzymes in an inactive form called zymogens, 
this is to prevent the pancreas digesting itself.  The most common enzymes include 
pancreatic protease, amylase and lipase. 
Duct cells – these produce bicarbonate which mixes with the zymogens to form 
pancreatic juice which flows into the duodenum.  The zymogen is only activated once 
it reaches the intestine and the bicarbonate neutralises acid entering the small 
intestine from the stomach. 
   
 
Figure 1.7 Normal pancreas stained by haematoxylin and eosin  51 
Malignancy 
Malignant is defined by the National Cancer Institute as “A term for diseases in which 
abnormal cells divide without control and can invade nearby tissues. Malignant cells 
can also spread to other parts of the body through the blood and lymph systems.  
Also called cancer”.   
In order to appreciate and understand malignancy we must first study the structure 
and function of normal tissues and organs.   
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1.3.1 Pancreatic cancer 
Pancreatic cancer is the tenth most common cancer in the UK and makes up 2.55% 
of all cancers. 52 
The biggest challenge faced by oncologists treating patients with pancreatic cancer is 
the limited clinical action of gemcitabine on the tumour.  Gemcitabine is the first line 
treatment for pancreatic cancer, used both singly and in combination with erlotinib.  
Only around 10% of pancreatic tumours are suitable for potential resection, which 
combined with adjuvant chemotherapy results in a 5-year survival rate of less than 
20%. 53 
 
1.3.1.1 Incidence and survival rates of pancreatic cancer 
Pancreatic cancer is the fifth most common cause of tumour-related death in the UK.  
It accounts for 2% of all cancers worldwide. While it is the twelfth most common 
cancer in males in the UK – less than 3% of all cancers – it is the eighth most 
common cancer in females in the UK, accounting for 3% of all cancers. Around 95% 
of pancreatic cancers originate in the exocrine part of the pancreas and the majority 
of these are ductal adenocarcinomas.  Tumours arising from the endocrine part of 
the pancreas are rare. 54 
 
    
 Table 1.5 New cases and rates of pancreatic cancer in the UK in 2010 55 
 
The average survival time for a pancreatic cancer patient following surgical resection 
is approximately 11-20 months.  This drops to 6-11 months in unresectable localised 
Pancreatic Cancer  England Wales Scotland Northern 
Ireland 
UK 
Male Cases 3,497 260 343 89 4,189 
Female Cases 3,561 260 353 100 4,274 
Persons Cases 7,058 520 696 189 8,463 
Crude rate = incidence per 100,000 people 
Male Crude 
Rate 
13.6 17.7 13.6 10.1 13.7 
Female Crude 
Rate 
13.4 16.9 13.1 10.9 13.5 
Persons Crude 
Rate 
13.5 17.3 13.3 10.5 13.6 
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tumour patients.  For patients with unresectable, metastatic disease the average 
survival time is 2-6 months. 56  
Less than 20% of patients have resectable tumours at initial diagnosis of the disease. 
 






1 year 15.3 16.1 15.7 
3 years 4.8 4.5 4.6 
5 years 3.6 2.9 3.2 
10 years - - - 
 
Table 1.6 Relative survival rates for pancreatic cancer for patients diagnosed  
       1983-2007 57 
 
The above table shows that in Scotland between 1983 and 2007, only around 15% of 
pancreatic cancer patients were still alive after one year and around 3% were still 
alive after 5 years.  No patients were alive at the 10 year milestone.  These statistics 
are shocking and due mainly to the fact that pancreatic cancer is diagnosed at a late 
stage of the disease.  The first symptoms with which most patients present to their 
GP are jaundice, both with and without abdominal pain. 
There is no screening programme in place for pancreatic cancer, possibly due to 
costs (a CT scan would be the most effective method of screening) and the relatively 
small portion of the population who are affected by pancreatic cancer. 
EUROPAC is the European Registry of Hereditary Pancreatitis and Familial Pancreatic 
Cancer. 58 They state that 5-10% of pancreatic cancers are hereditary and that, 
although many genes could be involved, the only one identified thus far is the BRCA2 
gene.  This organisation offers a screening service for people over 40 who are 
deemed high risk, but each patient is considered on a case-by-case basis.  The 
following methods may be used to screen patients: 
Fasting glucose – this is done to check the endocrine part of the pancreas is 
functioning normally. 
CA19-9 – this is a cancer antigen that is tested via a blood sample.  The drawback to 
this test is that it is not specific to pancreatic cancer, merely an indicator when 
evaluated alongside additional tests. 
Endoluminal ultrasound (EUS) – a small camera is inserted into the stomach via the 
gullet and images of the pancreas obtained. 
CT scan – a scan that produces a 3-D image of the pancreas. 
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Endoscopic Retrograde Cholangio-Pancreatography (ERCP) – very similar to EUS but 
a sample of pancreatic juice is taken for molecular analysis. 59 
 
1.3.1.2 Location and histological sub-types of pancreatic cancer 
 
Pancreatic cancer may be divided into categories based on the location and 
histological characteristics of the tumour.  Around 65% of cancers arise in the head 
and 30% arise in the body or tail of the pancreas.  The remaining 5% engulf the 
whole of the pancreas. 
Pancreatic ductal adenocarcinomas account for 85-90% of all pancreatic cancers and 
endocrine tumours account for less than 5% of all pancreatic cancers.  Acinar cell 
carcinomas make up 1-2% of all pancreatic cancers and the remaining types are 
relatively rare. 60 
 
1.3.1.3 Risk factors in pancreatic cancer 
(i) Age and sex – The number of cases reported in Scotland peaks for males 
between the ages of 70 and 74 before gently declining thereafter. 
For Scottish females reported cases peak between the ages of 80 and 84 and remain 
high. 61 
 
(ii) Ethnicity – Cases of pancreatic cancer are higher in persons of African descent 
or Ashkenazi Jews.  The reasons for this could be the high rates of smoking, diabetes 
and obesity in Africans and the prevalence of BRCA2 gene mutation in Ashkenazi 
Jews. 62 
 
(iii) Smoking and alcohol – smokers are 2 to 3 times more likely to develop 
pancreatic cancer than non-smokers.  Heavy drinkers – defined as 3 or more units of 
hard liquor per day – are 36% more likely to develop pancreatic cancer. 63 64 
 
(iv) Diet and obesity – the risk of developing pancreatic cancer increases with 
increased BMI.  Clinical research has shown that red meat consumption can increase 
the risk of pancreatic cancer; however there is no substantial evidence that a healthy 
diet decreases the risk. 65 66 
 
(v) Chronic pancreatitis – the risk increases in chronic pancreatitis sufferers by 
threefold.  The risk for inherited pancreatitis sufferers is far stronger, approximately 
45 to 70% greater. 67 68 
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(vi) Stomach ulcer – the risk is doubled in persons who have a stomach ulcer.  This 
could be related to the production of nitrosamines by bacteria present in ulcerated 
stomachs. 69 
 
(vii) Inflammatory bowel disease – long term inflammatory bowel conditions, e.g. 
ulcerative colitis or Crohn’s disease, increases the risk of pancreatic cancer, in some 
cases by 75%. 70 71 
 
(viii) Gum disease – recent research has shown a link between gum disease and 
increased risk of pancreatic cancer, however it is unclear why. 72  
 
(ix) Skin allergies – some research has shown that certain skin allergies such as 
eczema and hives can reduce the risk of pancreatic cancer.  This could be due to the 
fact that people who suffer from allergies have a more active immune system than 
those who don’t. 73 
 
(x) Family history – familial syndromes and genetic conditions account for 10% of 
all pancreatic cancers.   
 Hereditary pancreatitis is caused by germline mutations on the cationic 
trypsinogen 7q35 gene on and causes recurring bouts of acute pancreatitis.  
Pancreatitis is a risk factor for pancreatic cancer, therefore people with this 
condition have an increased risk of pancreatic cancer. 74 
 Familial atypical multiple mole melanoma (FAMMM) syndrome is caused by 
germline mutations on the p16 gene on 9p and increases the risk of 
developing both melanoma and pancreatic cancer. 75 
 Peutz-Jeghers syndrome is an autosomal dominant disorder caused by 
mutations on the serine/threonine kinase gene STK11(LKB1).  Sufferers of 
this syndrome have a 35% increased risk of developing pancreatic cancer. 76 
 
1.3.1.4 Diagnosis of pancreatic cancer 
The diagnosis of pancreatic cancer is virtually impossible in the early stages of the 
disease due to the fact it is symptomless.  Most cases are referred by the GP where 
patients have symptoms which could indicate many different diseases.  One of the 
most common presentations is jaundice and unexplained weight loss.  The GP may 
then check for the following symptoms: 
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 Jaundice 
 Swollen or tender abdomen 
 Presence of bile in the urine 
 Light coloured stools/darker than usual urine 
 Unintentional weight loss 
 Eating/digesting food problems 




 Itchy skin 
 Fever 
 
See Appendix 2 for diagnosis, staging and grading of pancreatic tumours. 
 
1.3.1.5 Treatment of pancreatic cancer 
Once a diagnosis has been confirmed, treatment options are determined by the 
stage, grade and location of the tumour, the patient’s age and general health.  Other 
factors that will influence treatment are the biological and genetic properties of the 
cancer cells.  The options available are surgery, radiotherapy and chemotherapy; 
often a combination of all three. 
Surgery 
Surgery for pancreatic cancer can be either curative or palliative.  The decision as to 
which type of surgery, if any, is determined by the size and location of the tumour 
and also the stage of the cancer.  Fitness to undergo surgery is also taken into 
consideration.  Surgical resection is only possible in 15-20% of cancers.  The most 
common pancreas surgery is a Whipple’s procedure and this is used for tumours in 













Figure 1.9 Pancreas post-Whipple’s procedure 77 
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For tumours occurring in the tail of the pancreas a distal pancreatectomy may be 
performed.  This involves removal of the body and tail of the pancreas, and often the 







Figure 1.10 Pancreas pre-distal pancreatectomy 77 
Figure 1.11 Pancreas post-distal pancreatectomy 77 
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If resection is not feasible then a stent may be fitted to allow the flow of bile or 
stomach contents.  
 
Radiotherapy 
Radiotherapy may be used both singly and in combination with chemotherapy.  It 
can also be used palliatively to allay pain by shrinking tumours that may be pressing 
on nerves or blood vessels or causing a blockage. 
Chemotherapy 
The standard chemotherapy first-line treatment for pancreatic cancer is gemcitabine 
or 5-fluorouracil (5-FU).  Capecitabine may also be given instead of 5-FU. 78 
The ESPAC I and III (European Study group for Pancreatic Cancer) clinical trials 
compared adjuvant chemotherapy with chemoradiotherapy.  The outcome of these 
trials resulted in a change in standard clinical practice favouring adjuvant 
chemotherapy.  79  The ESPAC IV trial is ongoing comparing gemcitabine as a 
monotherapy with gemcitabine plus capecitabine. 
Chemotherapy may be used to shrink the tumour pre surgery. 
If the cancer is inoperable then chemotherapy may be given in a bid to shrink the 
tumour and prolong life.  Gemcitabine is the main drug used in these cases, both on 
its own and in combination with other drugs. 
These are the most common drugs used: 
 GEMCAP – gemcitabine and capecitabine used in combination have increased 
response rate and overall survival.  This is the first-line treatment for 
advanced, metastatic cancer. 
 FOLFIRINOX – a combination of leucovorin, 5-fluorouracil, irinotecan and 
oxaliplatin may increase overall survival time, although only by a few months.  
The side effects of this therapy are more severe and can only be given to 
people who can withstand them. 
 Gemcitabine plus nab-paclitaxel – in September 2013 the FDA approved this 
drug combination for metastatic pancreatic carcinoma.  Nab-paclitaxel is 
paclitaxel bound to albumin, which facilitates entry of the drug into the cell.  
Recent research suggests that when used in combination with gemcitabine, 
nab-paclitaxel may increase the accumulation of gemcitabine within the 
tumour cells. 
24 
When chemotherapy fails often other drugs are used in a bid to slow down 
tumour growth.  There is no second line therapy for pancreatic cancer as such, 
although recently it has been found that tumours may respond to FOLFOX 
therapy (folinic acid, 5-fluorouracil and oxaliplatin).  
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1.4 Drug therapies in colorectal and pancreatic cancer 
 
The 2 drugs which will be investigated in this project are 5-fluorouracil and 
gemcitabine. 
 
1.4.1 5-fluorouracil (5-FU) 
 
5-fluorouracil, or 5-FU, has been the first line drug for several solid cancers for the past 
40 years and remains the first line choice for colorectal cancer; however, the response 
to 5-FU when used as a monotherapy can be less than 20%. 3  This increases to 20-
30% when given in combination with leucovorin and up to 50% when used with 
irinotecan or oxaliplatin. 11  
 




Figure 1.12 Structure of 5-FU 
 
 
            Capecitabine or 5’-deoxy-5-fluorouridine (5’-DFUR)  
 
Figure 1.13 Structure of capecitabine       
5-FU is a pyrimidine analogue which has a similar 
structure to the pyrimidine molecules of DNA and RNA.  
Its structure is similar to that of uracil, but there is a 
fluorine atom at the C5 position instead of hydrogen. 
As a result of the structure of 5-FU it can be incorporated 
into DNA and RNA thus leading to cell death. 
Capecitabine is a prodrug of  
5-FU and can be given orally as 
opposed to intravenously as is 
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Figure 1.14 Metabolism of 5-FU 
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5-DFUR – 5-deoxyfluorouridine or doxyfluridine 
TP – thymidine phosphorylase 
DPYD – dihydropyrimidine dehydrogenase 
5-FUDR – 5-fluorodeoxyuridine  
DHFU – dihydrofluorouracil 
5-FUMP – 5-fluorouracil monophosphate 
5-FDUMP – 5-fluorodeoxyuracil monophosphate 
ORTP – orotate phosphoribosyltransferase 
TS – thymidilate synth(et)ase 
TK – thymidine kinase 
5-FUDP – 5-fluorouracil diphosphate 
5-FDUDP – 5-fluorodeoxyuracil diphosphate 
RRM1 – ribonucleotide reductase subunit M1 
RRM2 – ribonucleotide reductase subunit M2 
5-FUTP – 5-fluorouracil triphosphate 
5-FDUTP – 5-fluorodeoxyuracil triphosphate 
5-DFCR – 5-deoxyfluorocytidine 
CDA – cytidine deaminase 
Capecitabine  
 Carboxyl esterase  
 5-DFCR 
CDA 




 TP  
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5-DUMP – 5-deoxyuracil monophosphate 
5-DTMP – 5-deoxythymidine monophosphate 
5-DTTP – 5-deoxythymidine triphosphate 
Figure 1.14 shows the conversion of 5-FU to its 3 active states: 5-FDUMP, 5-FDUDP 
and 5-FDUTP.  Figure 1.15 shows the conversion of capecitabine to 5-FU. 
About 80% of 5-FU is metabolised to DHFU – an inactive form of drug – in the liver 
by DPYD.80  Within both tumour and normal cells, DPYD is the rate-limiting step of 5-
FU metabolism.  Thymidine phosphorylase (TP) catabolises the conversion of 5-FU to 
the active substrate 5-FUDR and also catabolises the prodrug 5-DFUR to 5-FU.  5-
DUMP works by inhibiting TS, which makes TS an ideal target for chemotherapeutic 
drugs as it is subsequently phosphorylated to thymidine triphosphate for use in DNA 
synthesis and repair.  Ribonucleotide reductase is an enzyme that produces 
deoxyoligonucleotides from ribonucleotides, a step that is essential for DNA synthesis 
and repair.  Human ribonucleotide reductase exists in two subunits RRM1 
(regulatory) and RRM2 (catalytic).81 82 Both subunits are necessary for enzymatic 
activity and are encoded by different genes on separate chromosomes.  RRM1 and 
RRM2 are both critical for DNA synthesis and have been evaluated by several studies 
as therapeutic targets in various cancers. Importantly, ribonucleotide reductase 
reduces 5-FUDP to 5-FDUDP.  5-FDUDP is subsequently dephosphorylated into 5-
FDUMP, the active 5-FU metabolite which inhibits TS.  This pathway operates 
independent of TP. 
 
1.4.1.2  5-fluorouracil resistance in cancer 
5-FU has been the drug of choice to treat colorectal cancer for the past 50 years.  
This is despite the fact that the response rate is only around 15% when it is used as 
a monotherapy and peaking at around 40-50% when used in combination with 
leucovorin.  Much research has taken place into the mechanisms of resistance to 5-
FU, but there are no definitive markers of resistance which could be used to predict 
response to the drug. 11  
Dihydropyrimidine dehydrogenase (DPYD) is the rate-limiting step of metabolism of 
5-FU into its active state in both tumour and normal cells.  Only around 20% of 
administered 5-FU is metabolised as 80% is broken down by DPYD.  It is responsible 
for converting 5-FU to dihydrofluorouracil (DHFU), an inactive form of the drug.  
Previous research has shown that intratumoural gene expression levels of DPYD is 
predictive of response to 5-FU – low DPYD expression equates to increased response. 
3 83   Increased levels of DPYD have been shown to be indicative of 5-FU resistance in 
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both clinical and pre-clinical studies.  Upregulated levels of DPYD in the liver have 
also been correlated with 5-FU resistance.80 84  
Positive factors for 5-FU response have been suggested to be gender, favouring 
females and tumour location, favouring colonic tumours over rectal. 85  
Thymidine phosphorylase (TP) is involved in the conversion of 5-FU to 5-
fluorodeoxyuridine (5-FUDR) and also 5-deoxyfluorouridine (5-DFUR) to 5-FU.  
Research is inconclusive re TP expression and sensitivity to 5-FU, although it could be 
hypothesised that increased expression would relate to sensitivity. 86 87 3 
If a patient is administered capecitabine instead of 5-FU then the two proteins 
involved in the conversion to 5-FU are cytidine deaminase (CDA) and thymidine 
phosphorylase (TP).  CDA is responsible for the catabolism of 5-deoxyfluorocytidine 
(5-DFCR) to 5-deoxyfluorouridine (5-DFUR).   
This is the second step in the conversion of capecitabine to 5-FU. 
Thymidylate synthase (TS) expression levels in colorectal cancer have been 
researched extensively as a single predictor of 5-FU resistance.  Research has shown 
that low expression is linked to 5-FU sensitivity and also that amplification is linked to 
5-FU resistance. 11 88 Low TS expression has been significantly linked with 5-FU 
sensitivity in females.  TS is phosphorylated to thymidine triphosphate which plays a 
key role in DNA synthesis and repair. 3 89 90   5-fluorodeoxyuracil monophosphate (5-
FDUMP) suppresses TS by forming a covalent ternary complex with 5, 10-
methylenetetrahydrofolate, and thus indirectly affects DNA synthesis.  This makes TS 
an ideal target for chemotherapeutic drugs. 
RRM1 and RRM2 expression levels have been investigated both pre-clinically and 
clinically, and decreased levels have been linked with resistance to 5-FU. 90 
Both ribonucleotide reductases have been quantified in colorectal tumour versus non-
tumour and it was hypothesised that increased expression in the tumour cells is 
linked with lymph node metastases.91 
Human equilibrative nucleoside transporter 1 (hENT1) is a transmembrane protein 
responsible for the transport of gemcitabine into the cell.  Recent research has shown 
that hENT1 expression in tumour samples of colorectal cancer was indicative of the 
clinical response to 5-FU - high hENT1 expression indicated a poor response to 5-FU.  
This was reversed when hENT1 was inhibited chemically in a colorectal cancer cell 
line.92 
Research has been undertaken to compare protein expression in colorectal primary 
tumours with the corresponding liver metastases.  This has indicated that expression 
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increases in the liver metastases and this should be considered when prescribing 5-
FU.  93 
To summarise, resistance to 5-FU in colorectal cancer may be predicted using a 
combination of the following: 
 
 
PROTEIN EXPRESSION  
TS Increased  
 













Gemcitabine is a nucleoside analogue used in the treatment of many solid tumours, 
including pancreatic cancer.  Until around 1997, 5-FU was the standard 
chemotherapy drug until it was found that gemcitabine conferred significantly 
increased survival times.  Since then gemcitabine has been the first line drug for local 
advanced and metastatic pancreatic cancer. 94 
 
 
1.4.2.1 Structure and metabolism of gemcitabine 
 
 
           Gemcitabine 
 




Gemcitabine is a an analogue of 
Cytosine Arabinoside (Ara-C), the 
difference being fluorine components on 
position 2’ of the furanose ring. 
The metabolism of gemcitabine results 
in inhibition of DNA polymerase and 





















                                           

































Figure 1.17 Metabolism of gemcitabine 
Inhibits 
Gemcitabine triphosphate 
(dFdCTP) is transported into 
the cell nucleus and 
incorporated into nucleotides 










dFdC – 2’, 2’ difluorodeoxycytidine or gemcitabine 
hENT1 – human equilibrative nucleoside transporter 
dFdCMP – 2’, 2’ difluorodeoxycytidine monophosphate or gemcitabine monophosphate 
CDA – cytidine deaminase 
DCK – deoxycytidine kinase 
dFdCDP – 2’, 2’ difluorodeoxycytidine diphosphate or gemcitabine diphosphate 
dFdU – 2’, 2’ difluorodeoxyuracil 
dFdUMP – 2’, 2’ difluorodeoxyuracil monophosphate 
dFdCTP – 2’, 2’ difluorodeoxycytidine triphosphate or gemcitabine triphosphate 
dCMP deaminase – deoxycytidine monophosphate deaminase 
RRM1 – ribonucleotide reductase subunit M1 
RRM2 – ribonucleotide reductase subunit M2 
NDPK – nucleoside diphosphate kinase 
TS – thymidylate synth(et)ase 
 
Figure 1.17 shows the conversion of gemcitabine to its active state, dFdCTP. 
Gemcitabine is hydrophilic and cannot traverse cell membranes by passive diffusion. 
Therefore, the presence and activity of human equilibrative nucleoside transporter 1 
(hENT1) is considered a possible important determinant of gemcitabine cytotoxicity 
and clinical efficacy.  Ninety per cent of gemcitabine is inactivated to dFdU 
(difluorodeoxyuridine) by cytidine deaminase (CDA), therefore reduced levels of CDA 
could correlate with increased gemcitabine activity.  Intracellular gemcitabine (dFdC) is 
phosphorylated by deoxycytidine kinase (DCK) in a rate-limiting step to gemcitabine 
monophosphate (dFdCMP) – DCK is inhibited by dFdCTP. 
RRM1 and RRM2 provide the precursors necessary for DNA synthesis.  They are 
responsible for catalysing the biosynthesis of deoxyribonucleotides from the 
corresponding ribonucleotides. 
 
1.4.2.2 Gemcitabine resistance in cancer 
Research has demonstrated that acquired and inherent chemoresistance of pancreatic 
cancer cells to gemcitabine is determined by the balance of DCK, RRM1, RRM2, and 
hENT1 gene expression, but not to that of any of the individual genes. The 
hENT1*DCK/RRM1*RRM2 expression ratio significantly correlates with resistance to 
gemcitabine in pancreatic cancer cells, including acquired gemcitabine-resistant cells, 
suggesting that a decrease of this ratio reflects inherent and acquired chemoresistance 
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of pancreatic cancer cells to gemcitabine and may be a key to understanding the 
variable effectiveness of gemcitabine among individual patients.  However, this same 
study found hENT1 expression levels did not change in resistance to gemcitabine. 95  
Lecca et al conducted a review of gemcitabine resistance and generated an almost 
identical formula - DCK/RRM1*RRM2 with the hypothesis that hENT1 is an independent 
indicator of resistance to gemcitabine. 128 
hENT1 protein expression was shown to be associated with increased overall survival 
and disease-free survival in pancreatic cancer patients who received gemcitabine, but 
not in those who received 5-FU. These results could indicate that hENT1 expression 
could possibly be a predictor of gemcitabine sensitivity in patients with pancreatic 
cancer. 96 
hENT1 expression has been shown to be an independent factor associated with 
survival in patients with pancreatic cancer; however hENT1 expression might be a 
possible new prognostic factor for chemosensitivity of pancreatic cancer to 
gemcitabine. 97 
Quantitative analysis of hENT1, DCK, RRM1, and RRM2 mRNA using FFPE tissue 
samples and evaluation of a combined gemcitabine score were deemed useful in 
predicting the sensitivity to gemcitabine-based adjuvant chemotherapy in patients with 
pancreatic ductal adenocarcinoma (PDAC). Also, quantitative analysis of these genes in 
tumour cells taken from fine needle aspiration (FNA) specimens was found useful in 
determining the treatment for patients with PDAC even when the tumour is 
unresectable. 98 
Thymidylate synth(et)ase (TS) is possibly the most researched protein in 5-FU 
resistance.  It is inhibited by dFdUMP which would result in increased activity of 
hENT1, which is inhibited by TS.  This is highlighted by the fact that TS inhibitors allow 
increased expression of hENT1, therefore TS expression could be indirectly involved in 
gemcitabine resistance. 
hENT1 is a transmembrane protein.  In order for transmembrane proteins to localise to 
the plasma membrane, they must have been processed without any errors.  Research 
has shown that hENT2 (a transmembrane protein also involved in the transport of 
gemcitabine across the membrane) can undergo disrupted localisation which results in 
resistance to gemcitabine despite being expressed. 99  Other research has shown that 
disruption of a triplet near the N-terminus, or the last eight C-terminal residues result 





To summarise, resistance to gemcitabine in pancreatic cancer may be predicted using 
a combination of the following: 
 
PROTEIN EXPRESSION  
hENT1 Decreased  
 









































1.5 Tissue Microarrays 
 
1.5.1 Tissue microarray (TMA) or whole sections 
 
Tissue microarrays (TMAs) comprise of one paraffin block with 2-1000 tissue cores.  
TMAs are constructed by taking individual cores (0.5-2 mm in diameter) from FFPE 
blocks and placing them into a master block in a grid format. 
 
 
As early as 1998, the process describing the technique for high throughput profiling of 
tumour specimens was published. 101 Since then, the use of TMAs has grown 
enormously. 102  There are pros and cons for the technique - on the plus side, large 
amounts of different tissue cores may be embedded into one paraffin block.  This not 
only preserves the original tissue section but saves money as the use of reagents is 
much diminished for TMAs.  On the minus side, a lot of time is spent marking out 
tumour areas on stained slides of whole sections.  This tends to be done by Biomedical 
Scientists or Research Assistants.  There is the possibility that the tumour area may be 
misinterpreted and the incorrect area cored.  This is mitigated by constructing the 
paraffin blocks in triplicate at the very least.  This also allows for tumour heterogeneity, 
ideally different histological areas of the whole block are taken.  Other research has 
shown that TMAs are equal to whole sections in heterogeneic tumour sections. 103 
There is also the risk of losing cores from the TMA when sectioning. 104  Again this is 
mitigated by constructing multiple blocks. 
Figure 1.18 TMA block and section 
stained haematoxylin and eosin 
(H&E) 
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To summarise, TMAs help preserve precious tissue samples, are very cost effective and 





1.5.2 Long term storage of TMA sections 
 
The time and effort taken to produce TMAs means that serial sections are cut in a bid 
to maximise the amount of tissue available.  These sections are invariably stored for 
future use and it is generally perceived that tightly wrapped sections stored at -20oC is 
the best method to preserve antigenicity.  DiVito et al found that the optimum storage 
Figure 1.19 Semi-automatic arrayer  
Figure 1.20 Set of 4 identical TMA blocks 
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for cut TMA sections was paraffin coating and storage in a nitrogen dehumidifier, 
although this was only assessed over a 3 month period. 106 
Karlsson and Karlsson compared the storage of TMA sections at room temperature, 4oC 
and -20oC.  No significant difference was found in the staining intensity of IHC and 
fluorescent in-situ hybridisation over a period of 1 year, with storage at 4oC slightly 
superior to the other conditions. 107 
There could be several reasons for this – tissue being processed in CPA and other 
accredited labs is adequately fixed and processed.  Small research labs cannot offer 
the same assurance.  Antigen retrieval methods are improving over time, which would 
appear to negate the decline in antigenicity over a period of time.  Also, the modern-
day highly-sensitive antibody detection kits are far superior to historic ones. 
These factors mean that TMA sections can be cut and stored for future use with the 
reassurance that DNA and RNA targets are preserved. 
 
1.6 Automated QUantitative Analysis (AQUA) 
1.6.1 Immunohistochemistry (IHC) 
 
Immunohistochemistry (IHC) or “brown staining” remains the standard practice for 
staining and quantifying protein expression in diagnostic labs worldwide.  IHC utilises 
immunological, histological and biochemical techniques to identify specific tissue 
components by means of a specific antigen/antibody reaction tagged with a visible 
label.  IHC makes it possible to visualise the localisation of specific cellular components 
within a cell or tissue.  Nowadays, the focus for IHC has shifted from being used as a 
diagnostic aid to being used as a prognostic and predictive tool by pathologists 
worlwide. This has changed the goalpost from a simple positive or negative dignosis to 
the need for quantitative analysis with the subcellular localisation of the protein.  There 
are many variables that may affect IHC staining and scoring: 
1) Fixation and processing, thickness of sections  
2) Storage medium of cut sections  
3) Antigen retrieval system used 
4) Staining method used  
5) Dilution of antibidy used 
6) Reagent validation 
7) Experience of technician 
8) Positive and negative controls used 
9) Subjective nature of scoring 108    
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Variables 1-8 can be addressed by implementing a quality control/assurance 
programme for all pre-clinical and clinical research, however the results will always 
remain subjective.   
AQUA (automated quantitative analysis) utilises an immunofluoresecent technique to 
identify and visualise the target protein.  The amount of protein expressed is calculated 
by dividing the intensity of fluorescence by the total area of tumour tissue scanned.  
The use of AQUA has been shown to be superior to and remove the subjectivity of IHC 
scoring by pathologists, which can only be described as semi-quantitative at best.  It is 
of vital importance that IHC is scored accurately as any discrepancies could lead to 
patients being misdiagnosed and even being prescribed the wrong treatment regimen. 
109 110 
 
1.6.2 Automated Quantitative Analysis (AQUA) 
Because of the subjectivity of IHC scoring there are a number of computer-based 
quantitative analysis packages commercially available. 
The AQUA system was first developed in the Department of Pathology at Yale 
University. 111    
Normally the pathologist will look at sections and score them – perhaps even using a 
written method in a bid to standardise the process – by looking at staining intensity 
and number of positive cells.  This method is neither accurate nor reproducible, the 
same pathologist can score the same section differently if it is done at different times. 
112 108 
AQUA utilises immunofluorescent (IF) based IHC rather than the conventional 
chromogenic staining to visualise protein expression.  Firstly, a cytokeratin mask is 
applied to the section to enable differentiation between tumour cells and cell stroma.  
Then antibody-conjugated fluoresecent dye is used to stain the target protein, instead 
of the diaminobenzidine (DAB)/immunoperoxidase (or brown staining) used in 
conventional IHC.  Finally, the a nuclear counterstain is used, which is 4,6-Diamidino-2-
phenylindole (DAPI) for AQUA instead of haematoxylin which is used in conventional 
IHC. 
Camp et al devised a series of algorithms that he called AQUA which allow rapid, high-
throughput analysis of TMAs.   
The first algorithm, called PLACE (Pixel based Locale Assignment for 
Compartmentalisation of Expression), separates tumour cells from the stroma and 
defines the subcellular compartments using fluorescent labels.  The target protein is 
then quantified and located using these fluorescent tags.  The amount of protein 
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expressed is calculated by dividing the intensity of fluorescence by the total area of 
tumour tissue scanned. 
The second algorithm, called RESA (Rapid Exponential Subtraction Algorithm), allows 
for analysis of overlapping subcellular compartments, despite the thickness of the 
tissue sections, by subtracting an out-of-focus image from a focussed one  based on 
pixel intensity, signal-to-noise ratio, and the expected compartment size. 111 
These algorithms were validated using oestrogen receptor positive (ER positive) breast 










Figure 1.21 Pancreatic TMA core showing  
1) DAPI-stained nuclei  
2) Cytokeratin mask 
3) Target protein 
4) All three   
DAPI – 
Nuclei 
Cy3 –  
Cytokeratin 




1.7 Aims and Objectives 
1.7.1 Quality 
This thesis aims to address the reported factors that may contribute to academic 
research results irreproducibility.  The constraints are the same for all academic 
researchers – lack of time and funds.  However, even with the limitations stated above, 
it is believed that this thesis is reproducible and transparent.  All quality measures 
taken for this project are described in Chapter 2. 
The primary objective of the quality aspect of the project is to produce and document 
the quality control/quality assurance actions implemented to ensure accuracy and 
reproducibility. 
 
1.7.2 5-FU and capecitabine resistance 
Despite major advances in research over the past 50 years, drug resistance still 
remains the major obstacle in many cancers. 
5-FU only has a response rate of 10-15% in advanced colorectal cancer, which 
increases to 40-50% when used in combination with other drugs.113  
This thesis aims to research and identify the mechanisms of resistance to 5-FU (and 
capecitabine) thus enabling oncologists to accurately predict who will benefit from 
these therapies and negate the need for unnecessary treatment.  The proteins involved 
in transforming capecitabine to 5-FU are CDA and TP. 114 The proteins involved in the 
metabolism of 5-FU to its active state are TS, DPYD, TP, RRM1, RRM2, CDA and 
hENT1. 3 88 90 92 
Three sets of TMAs have been constructed and will be utilised in this thesis – colorectal 
cancer all stages, colorectal primary cancer with matched liver metastases.  These will 
be analysed using AQUA to determine subcellular location and quantification of 
expression levels of the above proteins within tumour cells.  This will be correlated 
against various demographics including chemotherapy regimen received and overall 
survival time. 
The primary objective of this part of the project is to discover the proteins and the 
relationship (if any) between the proteins, which will predict response to these drugs. 
 
1.7.3 Gemcitabine Resistance 
Resistance to gemcitabine, either inherent or acquired, is a major problem for 
oncologists. 115 The clinical response to gemcitabine is less than 25%, and most 
tumours that initially respond will develop resistance.  This could be due to further 
mutations within the tumour cells or the heterogeneity of the existing tumour, which 
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allows a subset of the cells to continue to grow.  Due to the late diagnosis of 
pancreatic cancer, only 50% of patients diagnosed with this cancer are alive after 6 
months and the 5-year survival rate is less than 5%. 116 
These statistics are horrifying and because survival times are so short it is paramount 
that patients are given treatments that are effective.  This thesis will endeavour to 
identify the combination of proteins involved in resistance.  The proteins involved in 
the transport into the cell and conversion of gemcitabine to its active state are hENT1, 
CDA, DCK, RRM1 and RRM2. 78 95 98 One set of quadruplicate TMAs has been 
constructed of different grades of pancreatic cancer, and protein expression and 
subcellular location will be determined using AQUA analysis.    
This will be correlated against patient demographics including chemotherapy regimen 
received and overall survival time. 
The primary objective of this part of the project is to discover the proteins and the 
relationship (if any) between the proteins, which will predict response to gemcitabine. 
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2. Quality, Materials and Methods 
2.1 Quality 
2.1.1 Quality Management 





     
 
      
 
Quality management is a means of ensuring that a product or process attains the 
required level of quality.  Depending on the circumstances, the level of quality could be 
determined by either regulatory requirement or adherence to local requirements. 
This project utilised both quality control (QC) and quality assurance (QA) to ensure 
that all steps taken were transparent and reproducible.  This project utilised archival 
clinical material, therefore the standards aimed to be measured against were Good 
Clinical Practice (GCP) and Good Laboratory Practice (GLP). 
 
Emphasis was placed on the areas of study which could potentially influence the 
results wherever possible. A flowchart of study processes/ procedures and table of 
predicted risks and risk mitigation, to ensure accurate and reproducible results, is 
detailed below.  A work plan was produced prior to starting any lab work, and this can 





































   
   
   







Figure 2.1 Flowchart to show the order of work for this project 
Spreadsheet of potential cohort was generated by Tissue Governance using 
predefined search parameters 
Formalin fixed paraffin embedded (FFPE) blocks and corresponding H+E slides 
were collated 
Tissue microarrays (TMAs) were constructed in quadruplicate 
4µm sections were cut and stored, wrapped in foil, at -20oC prior to staining 
An antibody validation algorithm was created in a bid to verify that the 
antibodies used in this study reached the intended target 
Slides were stained using the validated antibodies 
Sections were analysed using automated quantitative analysis (AQUA)  
Data was collated and analysed 
Antibodies were optimised 
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The figure above shows a brief overview of the work undertaken and the order it was 
completed in.  This is explained in more detail in the methods section of this chapter. 
A QA programme was conducted throughout the duration of the study and a final QA 
report detailing the audits undertaken and any findings. 
 
 
Stage of project Possible risk Mitigation 
Spreadsheet of potential 
blocks 
Blocks contain no or 
inadequate tumour tissue 
All blocks were checked to 
ensure sufficient tumour 
tissue was present 
FFPE blocks and H+E slides 
collated 
Incorrect slide collected 
and marked out 
All blocks and slides were 
reconciled 
TMAs constructed Tumour area missed  
TMAs were constructed in 
quadruplicate 
TMAs constructed 
Transcription error on TMA 
map 
All TMA maps were 
reconciled against blocks 
and slides and QC checked 
by 2 people 
4µm sections cut and 
stored 
Storage conditions affect 
antigenicity 
Extra slides were cut and 
stored under different 
conditions prior to staining 
to ascertain optimum 
storage conditions were 
used 
Antibody validation 
algorithm created prior to 
any staining 
Antibodies not specific to 
target protein 
Western blots to see if 
band appeared at predicted 
molecular weight (MW) 
Antibody validation 
algorithm created prior to 
any staining 
Antibodies not specific to 
target protein 
Stained sections checked 
for cleanliness and target 
area of cell stained 
Antibody validation 
algorithm created prior to 
any staining 
Antibodies not specific to 
target protein 
Antibodypedia consulted to 
check if antibody validated 
by other researcher 
Slides stained Error whilst staining  
QA programme instigated 
and inspections carried out 
by an independent QA 
manager 
Section analysis using 
AQUA on 2 different pieces 
of equipment 
No correlation between 
results 
Results were compared 
and analysed to ensure 
correlation of results 
Data collection and analysis Error in data collation 
Data audit conducted by 
independent QA manager 
Data collection and analysis 
Data manipulated to 
enhance results 
Final study audit conducted 
by independent QA 
manager 
 
Table 2.1 Table of anticipated risks and mitigations.  These will be explained in 
greater detail in the methods section of this chapter. This list is not exhaustive but an 
example of the measures that may be taken by an investigator with limited time and 
funds. 
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2.1.1.1 Good clinical laboratory practice 
GCP is a set of guidelines which is primarily concerned with the rights and well-being of 
participants taking part in clinical trials, although there is a large section on the validity 
of data.117 
GLP is a set of standards applied to pre-clinical studies.118  Pre-clinical means 
laboratory work that involves animals or cell lines, not human samples.  The guidelines 
are focussed on the generation and validity of results, to ensure that the results 
produced are reliable and reproducible. 
Good clinical laboratory practice (GCLP) is a merging of these two sets of standards, 
thereby ensuring that the work being done in the lab is conducted to GLP standards 
whilst ensuring the rights and well-being of study participants is not compromised.119 
This study focussed on ensuring patient confidentiality as well as the generation, 


























2.2.1 TMA set 1 – Colorectal cancer TMA 
A cohort of patients was generated from the NHS Lothian Pathology Archive Database 
using the search terms “colorectal”, “adenocarcinoma” and “resection”.  A list was 
finalised which included both males and females of varying ages and all stages of 
colorectal cancer, who had undergone a resection procedure.  Ethical approval was 
granted by Scotland A REC (10/S1402/33) for the generic use of pathology archive 
tissue for research.  An abbreviated table of patient characteristics can be seen in table 
2.2 below.  A more detailed table of patient characteristics can be seen in Appendix 4. 
 
 
Table 2.2 Patient characteristics for patients with colorectal adenocarcinoma included 
in this study that underwent colonic resection 
 
The above 130 blocks were used to construct TMAs in quadruplicate which were cut 
and stained prior to AQUA analysis. The proteins stained immunofluorescently were 
TP, RRM1, RRM2, DPYD and TS.  The analysis was run using TMA Navigator, a 
Characteristic Number of patients Per cent % 
Sex 130 100 
Male 70 53.8 
Female 60 46.2 
Age (years) 130 100 
<50 8 6.2 
≥50 122 93.8 
Duke’s stage 130 100 
A 12 9.2 
B 45 34.6 
C 67 51.6 
D 3 2.3 
NK 3 2.3 
Maximum tumour diameter (mm) 130 100 
<25 12 9.2 
≥25 and <50 74 57 
≥50 and >100 36 27.7 
>100 5 3.8 
NK 3 2.3 
Tumour location 130 100 
Colon 110 84.6 
Rectum 19 14.6 
NK 1 0.8 
Tumour differentiation 130 100 
Moderate 104 80 
Moderate/poor 6 4.7 
Poor 15 11.5 
Well 3 2.3 
NK 2 1.5 
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statistical programme which automatically divides the cohort into three equal 
groups.   
Univariate analysis was performed to produce overall and disease free survival.  The 
analyses were conducted on: 
- All patients 
- Patients who received gemcitabine 
- Patients who did not receive any chemotherapy 
 
2.2.2 TMA set 2/3 – Colorectal cancer/matched liver metastases             
                                             TMA 
A cohort of patients was generated from the NHS Lothian Pathology Archive Database 
using the search terms “liver”, “adenocarcinoma”, “metastatic” and “colorectal”.  A list 
was finalised which included both males and females of varying ages with a primary 
diagnosis of colorectal cancer and confirmed liver metastases.   Ethical approval was 
granted by Scotland A REC (10/S1402/33) for the generic use of pathology archive 
tissue for research.  An abbreviated table of patient characteristics can be seen in table 
2.3 below.  A more detailed table of patient characteristics can be seen in Appendix 5. 
 
 
Characteristic Number of patients Per cent % 
Sex 68 100 
Male 40 59 
Female 28 41 
Age (years) 68 100 
<50 3 4 
≥50 65 96 
Maximum tumour diameter (mm) 68 100 
<25 10 15 
≥25 and <50 39 57.5 
≥50 and >100 13 19 
>100 2 3 
NK 4 5.5 
Tumour location 68 100 
Colon 40 58.5 
Rectum 27 40 
NK 1 1.5 
Tumour differentiation 68 100 
Moderate 56 82.5 
Moderate/poor 2 3 
Poor 7 10 
Well 2 3 
NK 1 1.5 
Table 2.3 Patient characteristics for patients included in this study who had a primary 
colorectal tumour and metastatic liver tumour(s) 
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2.2.3 TMA set 4 – Pancreatic cancer TMA 
A cohort of patients was generated using the NHS Lothian Pathology Archive Database 
using the search terms “pancreas”, “adenocarcinoma” and “Whipple’s resection”.  A list 
was finalised which included both males and females of varying ages and stages of 
pancreatic cancer.  Ethical approval was granted by Scotland A REC (10/S1402/33) for 
the generic use of pathology archive tissue for research.  An abbreviated table of 
patient characteristics can be seen in table 2.4 below.  A more detailed table of patient 
characteristics can be seen in Appendix 6.  Authorisation from Lothian Tissue 
Governance to retrieve archival FFPE blocks can be seen in Appendix 7. 
 
 
Table 2.4 Patient characteristics for patients with a diagnosis of pancreatic 
adenocarcinoma and underwent a pancreatic resection 
 
The above 120 blocks were used to construct TMAs in quadruplicate which were cut 
and stained prior to AQUA analysis. The proteins stained immunofluorescently were 
hENT1, DCK, RRM1, RRM2.  The analysis was run using TMA Navigator, a statistical 
programme which automatically divides the cohort into three equal groups.   
hENT1 – the data from all four TMAs was used for combat analysis and the median 
value of the 4 TMAs was used for the median analysis.  These two analyses were 
Characteristic Number of patients Per cent % 
Sex 120 100 
Male 66 55 
Female 54 45 
Age (years) 120 100 
<50 8 6.7 
≥50 112 93.3 
Maximum tumour diameter (mm) 120 100 
<25 21 17.5 
≥25 and <50 88 73.35 
≥50 and >100 10 8.35 
>100 0 0 
NK 1 0.8 
Tumour location 120 100 
Head of pancreas 82 68.35 
Body of pancreas 3 2.5 
Tail of pancreas 4 3.35 
Other  31 25.8 
Tumour differentiation 120 100 
Moderate 50 41.7 
Moderate/poor 12 10.0 
Poor 41 34.2 
Well 16 13.3 
NK 1 0.8 
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undertaken to see if the two methods of analysis produced conflicting results.  
hENT1 cytoplasmic expression was calculated using AQUA for both median and 
combat values. 
Lecca formula – this was used for multivariate analysis of the proteins involved in 
gemcitabine metabolism.  Details of the Lecca formula can be found in section 2.3.5.  
Both univariate and multivariate analysis were performed to produce overall and 
disease free survival.  The analyses were conducted on: 
- All patients 
- Patients who received gemcitabine 


































2.3.1 Tissue microarray 
Sections were cut from each donor block at 4µm using a Leica rotary microtome, 
model no. RM2235 and stained with haematoxylin and eosin (H+E): this stains the 
nuclei blue and the cytoplasm pink. Briefly, sections were dewaxed in 3 changes of 
xylene for 5 minutes each.  Slides were then rehydrated through a series of alcohols – 
100%, 100%, 80% and 50% - 2 minutes in each, then washed in running water for 2 
minutes. 
Slides were stained in Harris haematoxylin (supplied by Shandon) for 4 minutes and 
washed in running water for 2 minutes.  Slides were then placed in Scott’s tap water 
substitute until the sections turned blue.  The nuclei were checked microscopically to 
ensure the correct level of staining.  If too dark the slides were differentiated in 
acid/alcohol, washed in water and blued in Scott’s tap water substitute.  If too light 
they were placed in haematoxylin for a further 30 seconds and washed and blued as 
previously described.  Once the correct level of nuclear staining was achieved the 
slides were washed in running water for 2 minutes.  Slides were then stained in eosin 
(eosin Y aqueous stain supplied by Shandon) for 5 minutes and washed in running 
water for 1 minute.  The slide rack was allowed to drain well and slides dehydrated 
through alcohols – 50%, 80%, 100% and 100% - for 30 seconds, 30 seconds, 2 
minutes, 2 minutes.  Slides were cleared in 3 changes of xylene, 5 minutes each and 
mounted using DPX.   See Appendix 8 for SOP of staining method used.   
The slides were then examined microscopically and tumour areas marked out.  Tumour 
areas that appeared different histologically were taken in an attempt to ensure that 
tumour heterogeneity was taken into account.  It is logical to hypothesise that tumour 
which appears different under the microscope may possess different biological 
properties.  See Appendix 9 for SOP referred to during marking out the slides.   
Four 0.6mm cores were taken from each block and arrayed in quadruplicate in 
recipient paraffin wax blocks.  A manual tissue arrayer (Beecher, model MTA1) was 
used to construct the TMAs.  Histologically different areas were taken (where possible) 
to see if different tissue morphology corresponds to different expression of target 
proteins.  






Figure 2.2 H+E stained slide.   
This has been marked out by a pathologist, the black circles are areas of tumour and 
1/2 means that 1 out of 2 lymph nodes present on the slide contains metastatic 
adenocarcinoma.  The block to the right hand side of the slide is the tumour block the 
section on the slide came from.   
 
Slides and blocks were reconciled to ensure the correct slide had been marked out. 
4µm sections were cut from each TMA on a Leica rotary microscope and sections 
stored, separated by tissue and wrapped in foil in an airtight box, in a -20oC freezer.    
 
2.3.1.1 Quality control of TMAs and unstained slide storage conditions 
QC of TMAs 
All TMAs were constructed in quadruplicate.  During construction all slides/blocks were 
placed in order in a storage box.  The slides/blocks were reconciled against the TMA 
map by the researcher and an independent person.  Both persons then signed the TMA 
map as witness that the blocks were cored and recorded in the correct order.  Any 
discrepancies were noted and corrected. 
See Appendix 10 for an example of a TMA map. 
 
Unstained slide storage conditions 
3 unstained slides were selected from the same TMA and stored for 6 months at room 
temperature (RT), 4oC and -20oC.   
52 
These sections were then stained using the method described in section 2.3.3 IF 
staining, using a rabbit primary antibody against TP and the staining compared on all 3 
slides.   
The sections for this study were stored at -20oC however, research has shown that the 
storage temperature is not critical to retention of antigenicity and that storage at 4oC is 
slightly better. 120 
2.3.2 Antibody validation 
Antibody centred techniques such as Western blotting, enzyme-linked immunosorbent 
assay (ELISA), immunoprecipitation (IP), immunofluoresence (IF), 
immunohistochemistry (IHC) and reverse phase protein microarray (RPPA) are used in 
both clinical and research settings however, antibody validation is seldom implemented 
to ensure the quality, reproducibility and specificity of the antibodies.  The reasons for 
this could include lack of resources and time, as well as the poor quality of 
commercially available antibodies. Can we rely on the validity and specificity of 
antibodies currently employed in preclinical research and have confidence in the 
reliability of the data found in peer-reviewed publications?  121 
IHC is routinely used in the clinical setting, the results of which inform the clinician 
which treatment is best for the patient.  Antibody based procedures used in a research 
laboratory could ultimately be a source of direction for large pharmaceutical 
companies. 
The Human Protein Atlas (HPA) is a research project that aims to map out the human 
proteome using an antibody based approach.  Initiated in 2003, this project 
systematically generates and validates antibodies, using expression profiling against a 
range of normal tissues, cancer tissues and cell lines. 122  The information in the table 





















hENT1 Uncertain Nucleus/Cytoplasm/ 
Membrane 
Low to high 
expression in 
colorectal cancer 
and low to medium 
expression in 
pancreatic cancer 
TS Uncertain Cytoplasm/Membrane Medium to high 
expression on 
colorectal cancer 
and low to medium 
expression in 
pancreatic cancer 
DPYD Uncertain Cytoplasm/Membrane No expression in 
colorectal cancer 
and low expression 
in pancreatic cancer 
TP Supportive Nucleus/Cytoplasm Low to high 
expression in 
colorectal cancer 
and low to medium 
expression in 
pancreatic cancer 
RRM1 Uncertain Cytoplasm/Membrane Low to high 
expression in 
colorectal cancer 
and low to medium 
expression in 
pancreatic cancer 
RRM2 Supportive Cytoplasm/Membrane Low to medium 
expression on 
colorectal cancer 
and low expression 
in pancreatic cancer  
DCK No details in HPA No details in HPA No details in HPA 
CDA No details in HPA No details in HPA No details in HPA 
 
Table 2.5 A list of all antibodies used in this study and the level of validation achieved 
in the Human Protein Atlas.   
 
Only TP and RRM2 could be considered validated using the HPA.  Therefore, this 
project attempted to validate all antibodies prior to any staining being undertaken.  123 
An antibody validation algorithm was developed, which could be easily integrated into 
a research or clinical laboratory – see below.  It is anticipated that the process of 








































Antibody to be validated 
Is antibody validated on 
Antibodypedia? † 
 





Antibody staining consistent with predicted target 





Is positive control slide tissue “normal” 
tissue? If not, redo positive control with 





Antibody staining consistent with predicted 







What level of antibody validation is supplied by vendor? ‡ 
Level 1 = 0 points 
Level 2 = 5 points 
Level 3 = 10 points 
Knockdown with siRNA or 




Figure 2.3 Antibody Validation Algorithm 
                       











The above antibody validation algorithm was created in a bid to at least attempt to 
verify that the antibodies used for this study were specific to the target protein. 
Inspiration was taken from the CRUK prognostic/predictive biomarker roadmap, the 
human protein atlas and literature review.  The purchase of antibodies was capped at 
3 due to cost. 
Out of a potential 45 points, each antibody must score at least 30 points to be 
considered validated for use in research.  This algorithm is not exhaustive; however it 
is a method of validation for use in small research facilities that have no formal 
processes in place for antibody validation and limited funds. 
 
† Antibodypedia   www.antibodypedia.com   
This is an open-access database of commercially available antibodies against human 
protein targets.  The site provides information on the efficacy of antibodies within a 
range of techniques.  There is no subscription charge, the information available is free.  
Researchers submit their data generated for an antibody which will either validate or 
invalidate the efficacy of the antibody.  Details will include the supplier of the antibody, 
protocol used and application performed: Western blot, IHC, IF or FISH.  Staining 
images are also submitted and researchers are able to leave comments. Fulfilment of 
all these points will score 10 points. 124 
 
If there are no details for the particular antibody but details are present for the same 
antibody from the same supplier used for a different application – score 5 points. 
 
‡ Levels of validation by antibody vendor 
Level 1  
 very limited information on validation of antibody 
 brief background information on target with very few references 
 information is available on recommended applications and starting dilutions 
 no examples of successful use in these applications 
 no references from publications 
 Datasheet contains information on animal host and immunogen source – i.e. 
 whether it is a synthetic peptide or a purified protein 






This level of validation scores 0 points on the algorithm therefore there are no 
minimum criteria points to be met. 
 
Level 2  
As level 1 validation criteria with the following included: 
 no in-depth information on procedures for antibody validation 
 datasheet contains background information on target and immunogen source 
 Information is also available on the complete peptide sequence or the area 
 surrounding the phosphorylation site 
 Information is available on recommended applications and starting dilutions 
 at least one example of the antibody successfully reaching the appropriate  target in 
one of the recommended applications, e.g. a successful Western blot  on cells which 
express the target 
 
This level of validation scores 5 points on the algorithm.  A minimum of 3 out of 5 
criteria points must be reached to score 5 points. 
 
Level 3  
As levels 1 and 2 validation criteria with the following included: 
 contains a description of the validation procedures employed by the vendor,  e.g. a 
Western blot in multiple cell lines 
 details on the quality control measures implemented to ensure no variations  within 
different batches 
 stringent antibody validation protocol which includes different applications on  cell 
lines which express the target 
 Information is present on optimal dilutions and preferred buffer 
 
This level of validation scores 10 points on the algorithm.  A minimum of 2 out of 4 
criteria points must be reached to score 10 points. 
 
◊ Is positive control “normal” tissue, if not redo 
If the positive control tissue for an antibody is not “normal” tissue, it is renal carcinoma 
or epithelial ovarian cancer, then there is a chance that the target has been 
translocated within the cell due to either the disease or treatment of the disease. 
Therefore, if the epitope is clearly stained but not in the predicted area of the cell, it is 
reasonable to presume that the antibody has correctly identified the target protein.  





received.  An alternative positive control should be sought using “normal” tissue and 
the two sections compared and analysed by a pathologist. 
 
2.3.2.2 Antibody quality 
The above algorithm was applied to all antibodies purchased for this project. 
If the antibody failed to meet standards then the vendor was contacted and supplied 
with details.  See Appendix 11 for the standard email sent to antibody suppliers.  This 
process was continued until all antibodies were validated using the algorithm. 
The table below details some of the antibodies purchased and the response from the 
vendors whilst in the process of finalising antibodies to be used. 
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Pass  Supplier not 
contacted 
 





2.3.2.3 Western Blot 
Preparation of protein lysates and determination of protein content 
Protein lysate samples were prepared and stored at -80oC.  To summarise briefly, cell 
cultures were seeded into 14 cm (diameter) plates until 80-90% confluent.  When cells 
were ready the plates were washed in ice-cold PBS and lysed in ice-cold lysis buffer for 
5 minutes. Cells were scraped from culture dishes and centrifuged at 13,000 rpm for 
6min at 4ºC. The amount of protein present in the supernatant was determined using 
the bicinchoninic acid assay (BCA).  Samples were prepared into aliquots and stored at 
-80 ºC. 
The SOP used for the preparation of the protein lysates used in Western blots is 
described in Appendix 12.  The protein lysates used in this study had been prepared 
previously and stored at -80oC. 
The SOP used to determine the protein concentration in each lysate sample is detailed 




Western blots are used to detect protein levels by separating proteins on a 
polyacrylamide gel. Antibodies are used to detect the protein and the results are 
visualised using chemiluminescence.  
Aliquots of protein samples were prepared as described previously with 50µg of protein 
in each sample.  A 10% resolving gel was prepared, poured and left to set.  3.6% 
stacking gel was prepared and poured on top of the resolving gel.  A comb was 
immediately inserted to create wells, the comb removed once gel had set.  Protein 
samples and rainbow and New England markers were denatured by heating for 5 
minutes at 95oC and 26µl of each loaded onto the wells.  This was run at 120mA for 30 
minutes then 70mA for 4 hours.  The proteins were transferred to a permeabilised 
membrane by running at 30v at 4oC overnight.  Membranes were blocked by 
incubating for 1 hour at room temperature using blocking agent diluted 50:50 with 
PBS.  Primary antibody was diluted 1:1000 and incubated overnight at 4oC. From this 
point all steps were completed in the dark. Membranes were washed for 5 minutes X3 
with PBS/tween then incubated for 45 minutes at room temperature with blocking 
buffer (as described above) and secondary antibody diluted 1:10.  Membranes were 
washed for 5 minutes X3 in PBS/tween and 5 minutes X3 in PBS then blotted and left 






The SOPs used to perform Western blot are detailed in Appendix 14. 















1) Rainbow marker (161-0324 Biorad) 
2) NEB marker (P7708 New England biomarkers) 
3) MCF10A 
4) BT474 
5) MDA MB453 
6) MDA MB466 
7) SKBR3 
 
1) 26µl  
 
2) 26µl 
3-7)  26µl of each sample was 







Rabbit mAb, ab29538 
Dilution 1:1000 
 




1) Rainbow marker (161-0324 Biorad) 
2) NEB marker (P7708 New England biomarkers) 
3) MCF10A 
4) BT474 
5) MDA MB453 
6) MDA MB466 
7) SKBR3 
 
1) 26µl  
 
2) 26µl 
3-7)  26µl of each sample was 














1) Rainbow marker (161-0324 Biorad) 
2) NEB marker (P7708 New England biomarkers) 
3) MCF10A 
4) BT474 
5) MDA MB453 




1) 26µl  
 
2) 26µl 
3-7)  26µl of each sample was 






Supplier: Novus Biologicals 






















1) Rainbow marker (161-0324 Biorad) 
2) NEB marker (P7708 New England biomarkers) 
3) MCF10A 
4) BT474 
5) MDA MB453 
6) MDA MB466 
7) SKBR3 
 
1) 26µl  
 
2) 26µl 
3-7)  26µl of each sample was 









Rabbit polyclonal Ab 
Dilution 1:1000 
 
Goat anti-rabbit fluorescent 
dye 
Dilution 1:10 





6) MDA MB361 
7) MDA MB463 
8) T47D 
9) ZR75/1 
10) Rainbow marker (161-0324 Biorad) 
 
1) 26µl  
 
2-9)  26µl of each sample was 













Goat anti-rabbit fluorescent 
dye 
Dilution 1:10 





6) MDA MB361 
7) MDA MB463 
8) T47D 
9) ZR75/1 
10) Rainbow marker (161-0324 Biorad) 
1) 26µl  
 
2-9)  26µl of each sample was 









Supplier: Abcam, mouse 
monoclonal AB, ab115701 
Dilution 1:1000 
 























5) MDA MB361 
6) MDA MB463 
7) MDA MB453 
8) MDA MB468 
9) SKBR3 
10) ZR75/1 
11) Rainbow marker (161-0324 Biorad) 
1) 26µl  
 
2-10)  26µl of each sample 
was loaded with 50µg of 








Supplier: Cell Signaling, 
Rabbit mAb, #4654 
Dilution 1:1000 
 
Goat anti-rabbit fluorescent 
dye 
Dilution 1:10 




5) MDA MB361 
6) MDA MB463 
7) MDA MB453 
8) MDA MB468 
9) SKBR3 
10) ZR75/1 
11) Rainbow marker (161-0324 Biorad) 
1) 26µl  
 
2-10)  26µl of each sample 
was loaded with 50µg of 







Supplier: Cell Signaling, 
Rabbit mAb, #4307 
Dilution 1:1000 
 
Goat anti-rabbit fluorescent 
dye 
Dilution 1:10 








2.3.2.4 Immunohistochemical evaluation of antibody 
Sections were dewaxed in 3 changes of xylene for 5 minutes each.  Slides were then 
rehydrated through a series of alcohols – 100%, 100%, 80% and 50% - 2 minutes in 
each, then washed in running water for 2 minutes. 
The 0.1M sodium citrate/0.1M citric acid pH6 method of antigen retrieval was used by 
microwaving slides in a pressure cooker for 5 minutes on the high setting.  These were 
left to cool then washed in 0.05% PBS/tween for 5 minutes.  Endogenous peroxidase 
was blocked by incubating for 10 minutes with 3% hydrogen peroxide (H2O2).  Slides 
were rinsed X2 in 0.05% PBS/tween for 5 minutes and background staining blocked by 
incubating with Dako total protein blocking solution used undiluted for 10 minutes.  
The primary antibody was diluted with Dako antibody diluent at the predetermined 
optimal dilution and incubation time (see table 2.6). Slides were rinsed X3 in 0.05% 
PBS/tween for 5 minutes and incubated with Dako envision labelled polymer for 30 
minutes.  Slides were rinsed X3 in 0.05% PBS/tween for 5 minutes then incubated with 
diaminobenzidine (DAB) diluted in substrate buffer 1:50 for 10 minutes. 
Slides were washed for 10 minutes in running water then stained in Harris 
haematoxylin for 1 minute and washed in running water for 2 minutes.  Slides were 
then placed in Scott’s tap water substitute until the sections turned blue.  The nuclei 
were checked microscopically to ensure the correct level of staining.  If too dark the 
slides were differentiated in acid/alcohol, washed in water and blued in Scott’s tap 
water substitute.  If too light they were placed in haematoxylin for a further 10 
seconds and washed and blued as previously described.  Once the correct level of 
nuclear staining was achieved the slides were washed in running water for 2 minutes.  
The slide rack was allowed to drain well and slides dehydrated through alcohols – 
50%, 80%, 100% and 100% - for 30 seconds, 30 seconds, 2 minutes, 2 minutes.  
Slides were cleared in 3 changes of xylene, 5 minutes each and mounted using DPX. 
Each antibody was stained using the manufacturers’ recommended positive controls 
wherever possible and a negative control was also included in every antibody staining 
run.  The method used for IHC can be found in Appendix 15. 
The sections were analysed to check that: 
a) The staining was “clean”, there was no background non-specific  staining. 
b) The target area of the cell was stained by the antibody. 






See Appendix 16 for an example of the dilutions used and summary of steps for 
































Antibody name Supplier Cat No. Species Antigen 
retrieval 
IHC dilution Incubation time and condition 
hENT1 Abcam ab135756 Rabbit polyclonal Sodium citrate/ 
citric acid pH6 
1:50 1 hour at RT 
CDA Abcam ab82347 Rabbit polyclonal Sodium citrate/ 
citric acid pH6 
1:200 1 hour at RT 
DCK Abcam ab151996 Rabbit polyclonal Sodium citrate/ 
citric acid pH6 
1:25 Overnight at 4oC 
TS Abcam ab108995 Rabbit monoclonal Sodium citrate/ 
citric acid pH6 
1:25 1 hour at RT 
RRM1 Protein Tech 10526-1-AP Rabbit polyclonal Sodium citrate/ 
citric acid pH6 
1:100 1 hour at RT 
RRM2 Novus Biologicals NBP1-31661 Rabbit polyclonal Sodium citrate/ 
citric acid pH6 
1:100 1 hour at RT 
DPYD Cell Signaling 4654s Rabbit monoclonal Sodium citrate/ 
citric acid pH6 
1:50 1 hour at RT 
TP Cell Signaling 4307s Rabbit monoclonal Sodium citrate/ 
citric acid pH6 
1:25 1 hour at RT 
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hENT1 Epitomics Cat # T0108.  Predicted MW 55kDa CDA Epitomics Cat # T1049. Predicted MW 16kDa 
 
   









   














The figure above shows the Western blots and IHC performed as part of the antibody validation process.  The final lab work was undertaken at St. 
Andrews medical school labs using antibodies that had been validated there by lab personnel.  The table below shows the final antibodies used.  
       
                                                     












points is a 
PASS) 
RESULT 
hENT1 Abcam ab135756 5 10 10 5 30 PASS 
CDA Abcam ab82347 5 10 10 5 30 PASS 
DCK Abcam ab151996 5 10 10 5 30 PASS 
TS Abcam ab108995 10 10 10 5 35 PASS 




NBP1-31661 10 10 10 10 40 PASS 
DPYD Cell Signaling 4654s 10 10 10 5 35 PASS 
TP Cell Signaling 4307s 10 10 10 5 35 PASS 
Table 2.9 The final selection of antibodies used and the level of validation achieved. 










Sections were dewaxed in 3 changes of xylene for 5 minutes each.  Slides were then 
rehydrated through a series of alcohols – 100%, 100%, 80% and 50% - 2 minutes in 
each, then washed in running water for 2 minutes. 
The 0.1M sodium citrate/0.1M citric acid pH6 method of antigen retrieval was used by 
microwaving slides in a pressure cooker for 5 minutes on the high setting.  These were 
left to cool then washed X2 in 0.05% PBS/tween for 5 minutes.  Endogenous 
peroxidase was blocked by incubating for 10 minutes with 3% hydrogen peroxide 
(H2O2).  Slides were rinsed X2 in 0.05% PBS/tween for 5 minutes and background 
staining blocked by incubating with Dako total protein blocking solution used undiluted 
for 10 minutes.  The primary antibody was diluted as previously detailed and the 
mouse anti-cytokeratin tumour mask was diluted 1:50 with Dako antibody diluent and 
incubated overnight at 4oC.   Slides were rinsed X3 in 0.05% PBS/tween for 5 minutes 
and incubated for 1.5 hours in the dark with goat anti-mouse Alexa 555 diluted 1:25 in 
goat-rabbit HRP antibody solution.  All steps from hereon in were performed on the 
dark.  Slides were rinsed X3 in 0.05% PBS/tween for 5 minutes then treated with Cy5 
tyramide diluted 1:50 in target signal amplification diluent for 10 minutes.  Slides were 
rinsed X3 in 0.05% PBS/tween for 5 minutes then placed in 80% ethanol for 1 minute. 
Slides were left to air dry in complete darkness overnight.  Prolong gold anti-fade 
reagent with DAPI was used as a mounting agent and the slides coverslipped and left 
to dry overnight in complete darkness. 
See Appendix 17 for the method used to stain the sections using immunofluorescence 
(IF).    Each antibody was optimised (as previously described for IHC) and the optimal 


























with fluorescent tag 
Figure 2.6 Simplified IF process to 
























1:500 Overnight at 
4oC 






1:250 Overnight at 
4oC 






1:750 Overnight at 
4oC 


















































1:500 Overnight at 
4oC 
Table 2.10 Finalised list of primary antibody used at St. Andrews for IF 
73 
 
2.3.4 AQUA Automated QUantitative AnalysisTM 
 
 
Figure 2.7 AQUA image analysis hardware 
 
Because of the subjectivity of IHC scoring there are a number of computer-based 
quantitative analysis packages commercially available. 
The AQUA system was first developed in the Department of Pathology at Yale University. 125    
AQUA utilises an immunofluorescent (IF) based technique rather than the conventional 
chromogenic staining to visualise protein expression.  Firstly, a cytokeratin mask is applied to 
the section to enable differentiation between tumour cells and cell stroma.  Then antibody-
conjugated fluoresecent dye is used to stain the target protein, instead of the 
diaminobenzidine (DAB)/immunoperoxidase (or brown staining) used in conventional IHC.  
Finally, a nuclear counterstain is used, which is 4,6-Diamidino-2-phenylindole (DAPI) for 
AQUA instead of haematoxylin which is used in conventional IHC. 
Camp et al devised a series of algorithms that he called AQUA which allow rapid, high-
throughput analysis of TMAs.   
The first algorithm, called PLACE (Pixel based Locale Assignment for Compartmentalisation of 
Expression), separates tumour cells from the stroma and defines the subcellular 
compartments using fluorescent labels.  The target protein is then quantified and located 
using these fluorescent tags.  The amount of protein expressed is calculated by dividing the 
intensity of fluorescence by the total area of tumour tissue scanned. 
The second algorithm, called RESA (Rapid Exponential Subtraction Algorithm), allows for 





sections, by subtracting an out-of-focus image from a focussed one  based on pixel intensity, 
signal-to-noise ratio, and the expected compartment size. 125 
These algorithms were validated using oestrogen receptor positive (ER positive) breast 
cancer tissue and colon carcinoma comparing pathologist scoring with AQUA quantification. 
The theory behind AQUA is to visualise and quantify the protein of interest within each 
tumour core.  Cytokeratin (Cy3) is used to differentiate the epithelial tumour cells from the 
stroma, commonly referred to as the “tumour mask”.  It also allows subcellular localisation of 
the target protein in combination with DAPI, which is used to stain the nuclei. 112  That is, 
any area within the tumour mask area not stained with DAPI is deemed cytoplasmic. 
Cy5 is the fluorophore of choice for the target protein as it is brighter than other fluorescein 
dyes and there is minimal auto-fluorescence of tissue at this wavelength (670nm).  The 
reason for this is because intrinsic and induced auto-fluorescence emits at a wavelength of 
450-650nm and therefore does not compete with Cy5. 126 
AQUA not only quantifies the target protein expression within the tumour area, it 
differentiates between the nuclear and cytoplasmic expression.  Any cores lacking sufficient 
tumour (<5% of total area has cytokeratin mask) are automatically excluded. 
See Appendices 18 and 19 to see the methods used for AQUA image acquisition and AQUA 
image analysis respectively. 
 
 
  Figure 2.8 TMA core stained for AQUA 
Picture 1 shows nuclei only stained with DAPI 
DAP I  –  
Nuc le i  
Cy3  –   
Cy toke ra t in  
Cy5  –  Target  








Picture 2 shows the cytokeratin tumour mask – cytokeratin is used to determine the areas of 
each TMA core that are tumour 
Picture 3 shows the target protein expression in the same core 
Picture 4 shows pictures 1-3 merged so we can see target protein expression in the tumour 
area as well as the stroma 
 
2.3.5 Statistical analysis 
The statistical packages TMA Navigator and SPSS v21 were used for univariate and 
multivariate analysis. 
 
2.3.5.1 Lecca Formula 
Ozan Kahramanogullari, Gianluca Fantaccini, Paola Lecca, Daniele Morpurgo and Corrado 
Priami created an algorithmic model to quantify the metabolic inhibitions to gemcitabine 
efficacy.
128
  The nucleoside transporter hENT1 was deemed an independent factor in 
gemcitabine resistance as it is responsible for the transport of gemcitabine into the cell. 
DCK is responsible for the phosphorylation of gemcitabine to gemcitabine monophosphate.  
RRM1 and RRM2 are responsible for catalysing the biosynthesis of deoxyribonucleotides from 
the corresponding ribonucleotides.  Thus it is reasonable to hypothesise that increased 
survival time could be associated with high DCK and low RRM1/ RRM2 expression. 
Lecca et al created a final equation using DCK, RRM1 and RRM2:  
DCK/(RRM1*RRM2) 









3.1 Quality results 
3.1.1 Quality Assurance statement 
 
A QA programme was maintained throughout the duration of this project which included 
process inspections (these audit lab work undertaken against the relevant SOP) and data 
checking (to ensure accuracy and integrity of data) and final report checking (to ensure that 
the results generated were valid). 
A QA statement was written at the end of the study to confirm the integrity of the work 
undertaken and the data generated.  The full QA statement can be seen in Appendix 20. 
 
 
Figure 3.1 QA statement 






Figure 3.2 Slidepath image of pancreatic cancer TMA cores checked by the 
pathologist to indicate any cores that were not cancer.  These cores were not 
included in the analysis. 
 
 
3.1.2 Comparison of AQUA scores between St. Andrews and Edinburgh 
The graphs below show the results of pancreatic cancer TMA1 stained using CDA.  
The slides were scanned using the AQUA facility at both St. Andrews and Edinburgh 
labs and the expression levels from both plotted.  This was undertaken to ensure 
correlation of results from the two pieces of equipment. 
 
  







The correlation coefficient – or r – of the above scores is 0.999455, which shows a strongly 
positive correlation.  The coefficient of determination – or r2 – is 0.9989103.  This means that 
99.89 % of the total variation in Edinburgh scores can be explained by the linear relationship 
between St Andrews and Edinburgh scores. 
 
  
 Figure 3.4 Comparison of AQUA cytoplasm scores between Edinburgh and St.  Andrews  
 
   
The correlation coefficient – or r – of the above scores is 0.999940107, which shows 
a strongly positive correlation.  The coefficient of determination – or r2 – is 
0.99988022.  This means that 99.99% of the total variation in Edinburgh scores can 
be explained by the linear relationship between St Andrews and Edinburgh scores. 
 
 
3.1.3 TMA Slide Storage Conditions 
The long-term storage of TMA slides may result in a loss of antigenicity, presumably 
due to oxidation of exposed proteins. 
TMA slides were cut, wrapped in foil and stored for 6 months at RT, 4oC and -20oC.  
The slides were then stained for IF using the method described in Chapter 2 using the 
TP antibody.  The expression levels varied according to the temperature they were 






Interpreting these results would indicate that the optimum storage conditions for cut 
TMA sections are -20oC. 
The pictures below show AQUA generated images of sections stored under the 3 
different conditions.  The expression, or AQUA score, is determined by the pixel 
intensity (or fluorescence) of the target protein in the cytoplasm or nucleus (or both).  









Stored at room temperature showing 
nuclear expression in left hand image and 









Stored at 4oC showing nuclear expression 
in left hand image and higher 




Stored at -20oC showing nuclear 
expression in left hand image and higher 




Figure 3.5 Pancreatic cancer TMA1 spot 56 stained with TP after storage for 6 months at RT, 4oC and -20oC.  The values for AQUA nuclear and 
cytoplasm expression are given.  Expression levels increase as the temperature decreases, indicating -20oC is the optimum long term storage 








Stored at room temperature showing 
nuclear expression in left hand image 










Stored at 4oC showing nuclear 
expression in left in right hand image 






Stored at -20oC showing nuclear 
expression in left hand image and higher 
magnification in right hand image 14517.0 12865.9 




Figure 3.6 Pancreatic cancer TMA1 spot 62 stained with TP after storage for 6 months at RT, 4oC and -20oC.  The values for AQUA nuclear and 
cytoplasm expression are given.  The values for AQUA nuclear and cytoplasm expression are given.  Expression levels increase as the temperature 







Stored at room temperature showing 
nuclear expression in left hand image 










Stored at 4oC showing nuclear 
expression in left hand image and higher 





Stored at -20oC showing nuclear 
expression in left hand image and higher 





Figure 3.7 Pancreatic cancer TMA1 spot 92 stained with TP after storage for 6 months at RT, 4oC and -20oC.  The values for AQUA nuclear and cytoplasm 
expression are given.  The values for AQUA nuclear and cytoplasm expression are given.  The cytoplasm expressions are similar at all temperatures with 
the highest expression level at 4oC.  The nuclear expression levels concur, with the highest expression at 4oC.  Interestingly, the lowest expression level is 






3.2 Pancreatic cancer and gemcitabine resistance results 
   Table 3.1 Patient demographics, clinical characteristics, and histopathological  features for 
  pancreatic cancer cohort combat data  
 
The above demographics were collated by the Tissue Governance team in NHS 
Lothian.  Results are shown as a percentage of the total in the final column. 
There is an almost even split between the sexes, with 54% males and 46% females. 
Ages ranged from 43 – 84 with the median age of 66 and the most common location 
for tumours being the head of the pancreas (76.5% of the cohort).  Most patients were 
diagnosed at a late stage of the disease – 87% at pathologic stage T3 and 68% with 
nodal involvement.  Due to the proximity of the pancreas to other organs 75% of 
patients had positive resection margins. 
Interestingly, 82.5% of patients showed perineural invasion and 76.5% showed 
lymphovascular invasion. 
  
Variables Number of patients Per cent % 
Gender 85 100 
Male 46 54 
Female 39 46 
Age (years)   
Median 66 - 
Range 43 - 84 - 
Tumour location   
Head/tail/ampulla/common bile duct 65/3/5/2/10 76.5/3.5/6/2.5/11.5 
Maximum tumour diameter (mm)   
Mean (+/- SD) 35.56 +/- 10.68 - 
Median 32 - 
Range 15 - 72 - 
Pathologic stage   
T1/T2/T3/T4 3/6/74/2 3.5/7/87/2.5 
N0/N1/Nx 15/68/2 17.5/80/2.5 
MX/M1/NK 31/2/52 36.5/2.5/61 
Tumour differentiation   
Moderate/moderate-poor/poor/well 36/11/28/10 42.5/13/33/11.5 
Surgical margins   
Positive/negative 64/21 75/25 
Perineural invasion   
Yes/no/NK 70/9/6 82.5/10.5/7 
Lymphovascular invasion   
Yes/no/NK 65/14/6 76.5/16.5/7 
Pancreatitis   























    Figure 3.8 AQUA immunofluorescence images showing expression of the 5                  
    proteins involved with gemcitabine transport and metabolism  
 
Figure 3.8 above shows the 5 proteins involved in the transport and metabolism of 
gemcitabine.  The cores on the left show low expression and the cores on the right 
show high expression.  These pictures were generated using AQUA software and show 

















3.3 Statistical analysis 
3.3.1 Median values versus complete dataset 
After consideration it was decided to complete what are effectively two sets 
of statistical analyses using  
1) Median values of the four identical TMA blocks  
2) All values (combat data) 
The reasons for doing this were as follows: 
 Median values best reflect the current practices of a hospital pathology department.  
When a tumour section is being assessed by the pathologist the largest area of 
tumour showing a particular feature – for example differentiation, tumour type, 
HER2 status – will determine how the tumour is classified.  Any different features 
are noted in the pathology report but not acted on.  By using only the median 
values, any extreme values which could potentially skew the results will be 
removed or not acted on. 
 All values were used to take into account tumour heterogeneity.  Very rarely, if ever, 
would a tumour show consistent features throughout, therefore it could be 
hypothesised that extreme values represent the histologically different areas of 
tumour. 
 
3.3.2 Interpretation of statistical results 
Univariate analysis was completed on both median values and combat data within the 
complete patient group were analysed using TMA Navigator, which is a free web-based 
program specifically created to analyse TMA data.127 This was to examine each protein 
singly to see if it could predict survival – disease free and overall - within a patient 
group.  The worst prognostic group in each case was selected and compared against 
the group of patients who received chemotherapy. 
For colorectal TMAs the chemotherapy group had received 5-FU or capecitabine and 
for pancreatic TMAs the chemotherapy group had received gemcitabine.   
Analysis on the complete patient group was completed to see if any of the proteins 
were predictive of survival.  Analysis on the group who received chemotherapy was 
compared against the complete patient group to see if any proteins that predicted 
survival were also significant prognostically.  Finally, the equation generated by Lecca 
et al was used to determine whether combination of proteins were predictive of 
resistance.128  This formula uses the equation DCK/(RRM1 x RRM2) to generate a 




hypothetically an independent indicator of gemcitabine resistance therefore univariate 
analysis results were generated for this protein. 
 
3.4 Statistical analysis for overall survival of pancreatic TMA 
set 
 
3.4.1 Marker heatmaps and Spearman’s correlation networks for all 
data 
 
      Median values                             Combat data  
  
Figure 3.9 Pancreatic cancer TMA marker heatmap for median values and combat 
data for all patients 
 
The above heatmaps were generated using TMA Navigator.  The orange colour 
indicates a positive correlation and the blue colour indicates a negative correlation, any 
grey shades indicate no correlation.  The proteins are listed along the bottom and 
down the right hand side.  
Both median and combat values indicate that there is a strong negative correlation 
between TP and DPYD.  There is weaker negative correlation between CDA and TP 
with TS and DPYD and RRM2. 
The dendogram to the left and top of the diagram shows the proteins grouped 
together using agglomerative hierarchical clustering.  This is a bottom up method 
which builds a hierarchy of clusters which shows relations between individual members 
and merges clusters of data based on similarity. 129  This is used to look at trends 







Figure 3.10 Spearman’s correlation network for pancreatic cancer TMA using combat 
values of all patients  
 
Spearman’s correlation coefficient, or Spearman’s rho, is a measure of statistical 
dependence between 2 variables.  It determines the relationship between variables 
using a monotonic function; this means the values between the 2 variables increase or 
decrease in a similar fashion.  Perfect correlation is either: 
1 = strong orange shade on figures 3.8 and 3.9 or 
-1 = strong blue shade on figures 3.8 and 3.9 
This network sorts the 2 sets of data into ranks and tests for correlation, which means 
that each of the variables either increased or decreased consistently with respect to 
each other.  The p value for this analysis was set at 0.05. 
Figure 3.11 shows the correlation between the 8 proteins of interest in both nucleus 
and cytoplasm.  A thick grey line between pairs of proteins indicates a strong 
correlation and a thinner grey line indicates a lesser correlation. 
The table below give the Spearman’s rho and p values for the pairs of proteins shown 










Pair of proteins (combat data) Spearman’s rho P value 
DCKnuc – DCKcyt 0.94 0 
hENT1nuc – hENT1cyt 0.88 0 
CDAnuc – CDAcyt 0.88 0 
RRM1nuc – RRM1cyt 0.89 0 
RRM2 nuc – RRM2 cyt 0.83 0 
TPnuc – TPcyt 0.92 0 
DPYDnuc - DPYDcyt 0.87 0 
TSnuc – TScyt 0.84 0 
DCKnuc – RRM1cyt 0.50 0.005 
 
Table 3.2 Spearman’s rho and p values for pairs of proteins within pancreatic cancer 




Figure 3.11 Spearman’s correlation network for pancreatic cancer TMA using median 
data of all patients 
 
This is the same patient set as figure 3.11 but using median values instead of all data.  
The table below give the Spearman’s rho and p values for the pairs of proteins shown 







Pair of proteins (median values) Spearman’s rho P value 
DCKnuc – DCKcyt 0.93 0 
hENT1nuc – hENT1cyt 0.89 0 
CDAnuc – CDAcyt 0.91 0 
RRM1nuc – RRM1cyt 0.85 0 
RRM2 nuc – RRM2 cyt 0.81 0 
TPnuc – TPcyt 0.91 0 
DPYDnuc - DPYDcyt 0.87 0 
TSnuc – TScyt 0.88 0 
DCKnuc – RRM1cyt 0.53 0.003 
DCKnuc – RRM2cyt 0.50 0.006 
DCKnuc – TPcyt 0.47 0.018 
DCKcyt – RRM2cyto 0.54 0.002 
TPcyt - CDAcyt 0.46 0.020 
TPcyt - CDAnuc 0.45 0.032 
 
Table 3.3 Spearman’s rho and p values for pairs of proteins within pancreatic cancer 
TMA using median values of all patients 
 
DCK nucleus and RRM1 cytoplasm are significantly correlated using both median values 
and combat data.  DCK nucleus is also linked with RRM2 cytoplasm and TP cytoplasm.  
DCK cytoplasm is linked with RRM2 cytoplasm.  TP cytoplasm is linked with CDA 
cytoplasm and nucleus. 
 
Overall and disease free survival for all cohorts of pancreatic cancer TMA can be seen 












3.5 Statistical analysis using Lecca formula 
3.5.1 Kaplan-Meier survival plots of all patients pancreatic TMA set 
Overall survival 
The graph below shows the overall survival in months of all patients in the pancreatic 
cancer cohort.  Some of these patients will have received various chemotherapeutic 
treatments and some will have had no treatment.  The analysis was run using TMA 
Navigator, a statistical programme which automatically divides the cohort into three 
equal groups.  If we look at the survival rates we see that no patients survived past 51 
months in the low and medium expression groups.  All patients in the high expression 
group had died by 67 months.  These results are not statistically significant with a p 
value of 0.24.  Details on the Lecca formula can be found in section XX 
 
 





[P value] odds ratio and 95% 
confidence intervals 
 
1(23) L 0.00 - 236.54 (175.18) Low-Medium [0.26] 0.68(0.35 – 1.37) 
2(22) M 244.58 - 370.96 (302.62) High-Medium [0.77] 1.1 (0.59 – 2.06) 
3(23)  H 376.71 - 737.81 (453.18) Low-High [0.16] 1.61(0.82 – 3.14) 
 
Figure 3.12 Kaplan-Meier survival plot of pancreatic cancer TMA using Lecca formula 
showing overall survival of all patients: Lecca formula = DCK/(RRM1 x RRM2) 




Disease free survival 
The graph below shows the disease free survival in months of all patients in the 
pancreatic cancer cohort.  Some of these patients will have received chemotherapeutic 
treatment and some will have had no treatment.  The analysis was run using TMA 
Navigator, a statistical programme which automatically divides the cohort into three 
equal groups.  All patients in the low and medium expression groups succumbed to 
disease progression by 39 months.  9% of patients in the high expression group were 
disease progression free at 58 months, however this result is not statistically significant 









[P value] odds ratio and 95% confidence 
intervals 
 
1(23) 0.00 - 236.54  (175.18) Low-Medium [0.47] 1.27 (0.67 – 2.4) 
2(22) 244.58 - 370.96 (302.62) High-Medium [0.39] 0.75 (0.38 – 1.46) 
3(23) 376.71 - 737.81 (453.18) Low-High [0.12] 1.7 (0.87 – 3.33) 
 
Figure 3.13 Kaplan-Meier survival plot of pancreatic cancer TMA using Lecca formula 
showing disease free survival of all patients: Lecca formula = DCK/(RRM1 x RRM2) 
 




3.5.2 Kaplan-Meier survival plots of patients who had no 
chemotherapy pancreatic TMA set 
Overall survival 
The graph below shows the overall survival in months of the patients in the pancreatic 
cancer cohort who did not undergo any chemotherapeutic treatment.  The analysis 
was run using TMA Navigator, a statistical programme which automatically divides the 
cohort into three equal groups.  The low and medium expression groups survival lines 
are almost identical with no patients surviving past 19 months.  This compares to the 
high expression group where 25% of patients were still alive at 48 months.  This result 
is not statistically significant with a p value of 0.24. 
Details on the Lecca formula can be found in section 2.3.5.1. 
 
p = 0.24 
Group  




[P value] odds ratio and 95% confidence 
intervals 
 
1 106.08 - 280.86 (188.49) Low-Medium [0.84] 1.15 (0.3 – 4.39) 
2 281.29 - 412.44 (328.39) High-Medium [0.23] 2.75 (0.52 – 14.53) 
3  433.30 - 721.68 (514.04) Low-High [0.2] 3.15 (0.54 – 18.41) 
Figure 3.14 Kaplan-Meier survival plot of pancreatic cancer TMA using Lecca formula 
showing overall survival of patients who had no chemotherapy: Lecca formula = 
DCK/(RRM1 x RRM2) 
 




Disease free survival 
The graph below shows the disease free survival in months of the patients in the 
pancreatic cancer cohort who did not undergo any chemotherapeutic treatment.  The 
analysis was run using TMA Navigator, a statistical programme which automatically 
divides the cohort into three equal groups.  The low and medium expression survival 
lines are almost identical with all patients showing disease progression at 15 and 18 
months respectively.  This compares to the high expression group where 25% of 
patients were progression free at 30 months.  This result is not statistically significant 
with a p value of 0.20.  Details on the Lecca formula can be found in section 2.3.5.1. 
 
 
p = 0.20 
Group  




[P value] odds ratio and 95% confidence 
intervals 
 
1 106.08 - 280.86 (188.49) Low-Medium [0.86] 1.13 (0.29 – 4.38) 
2 281.29 - 412.44 (328.39) High-Medium [0.2] 2.96 (0.56 – 15.6) 
3  433.30 - 721.68 (514.04) Low-High [0.18] 3.35 (0.57 – 19.6) 
 
Figure 3.15 Kaplan-Meier survival plot of pancreatic cancer TMA using Lecca formula 
showing disease free survival of patients who had no chemotherapy: Lecca formula = 
DCK/(RRM1 x RRM2) 
 




3.5.3 Kaplan-Meier survival plots of patients who received 
gemcitabine pancreatic TMA set 
Overall survival 
The graph below shows the overall survival in months of the patients in the pancreatic 
cancer cohort who received gemcitabine.  The analysis was run using TMA Navigator, a 
statistical programme which automatically divides the cohort into three equal groups.  
The longest survival time of the low expression group was 14 months, compared to 39 
months for the medium expression group and 80 months for the high expression 
group.  This result is statistically significant with a p value of 0.007. Details on the 
Lecca formula can be found in section 2.3.5.1. 
 
 






[P value] odds ratio and 95% confidence 
intervals 
 
1  0.00 - 212.70 (191.22) Low-Medium [0.05] 0.216 (0.05 – 1.02) 
2  236.54 - 310.16 (288.98) High-Medium [0.009] 9.77 (1.75 – 54.4) 
3  317.70 - 737.81 (388.77) Low-High [0.31] 2.11 (0.5 – 8.9) 
 
Figure 3.16 Kaplan-Meier survival plot of pancreatic cancer TMA using Lecca formula 
showing overall survival of patients who received gemcitabine: Lecca formula = 
DCK/(RRM1 x RRM2) 
 




Disease free survival 
The graph below shows the disease free survival in months of the patients in the 
pancreatic cancer cohort who received gemcitabine.  The analysis was run using TMA 
Navigator, a statistical programme which automatically divides the cohort into three 
equal groups.  The low, medium and high expression groups showed all patients 
having succumbed to disease progression at 23, 13 and 50 months respectively.  This 
result is not statistically significant with a p value of 0.07. 
Details on the Lecca formula can be found in section 2.3.5.1. 
 






[P value] odds ratio and 95% confidence 
intervals 
1  0.00 - 212.70 (191.22) Low-Medium [0.37] 0.52 (0.14 – 1.95) 
2  236.54 - 310.16 (288.98) High-Medium [0.05] 4.52 (0.99 – 20.6) 
3  317.70 - 737.81 (388.77) Low-High [0.24] 2.37 (0.56 – 9.98) 
 
Figure 3.17 Kaplan-Meier survival plot of pancreatic cancer TMA using Lecca formula 
showing disease free survival of patients who received gemcitabine: Lecca formula = 
DCK/(RRM1 x RRM2) 
 
 




3.6 Statistical analysis of cytoplasm hENT1 
3.6.1 Kaplan-Meier survival plots of all patients pancreatic cancer TMA 
set 
The graphs below show the overall survival plotted against cytoplasmic expression of 
hENT1 for all pancreatic cancer patients in this cohort.  Some of these patients would 
have received chemotherapeutic intervention and some would have no treatment.  The 
analysis was run using TMA Navigator, a statistical programme which automatically 
divides the cohort into three equal groups.  The TMAs were constructed in 
quadruplicate – the data from all four TMAs was used for combat analysis and the 
median value of the 4 TMAs was used for the median analysis.  These two analyses 
were undertaken to see if the two methods of analysis produced conflicting results.  
The expression, or AQUA score, is determined by the pixel intensity (or fluorescence) 
of the target protein in the cytoplasm or nucleus (or both).  This value is normalised by 
calculating the total tumour area and light exposure time.104  If the total tumour area is 
less than 5% of the total area of the spot then it is automatically excluded from 
analysis. 
Comparing the graphs, there is little difference between median and combat analysis 
and there is no definitive separation of the groups.  In the median values graph the 
low expression group survived longest whereas in the combat values graph the 
medium expression group survived longest.  The p values are 0.37 and 0.55 for 




Median values Combat data 
  















1 (25) 77.33 – 186.96 142.01 1 87.89 - 187.82 141.75 
2 (24) 187.82 – 251.22 229.68 2 191.55 - 254.57 226.27 
3 (24) 254.57 – 1254.99 475.33 3 254.90 - 1625.25 451.38 
[P value] odds ratio and 95% confidence 
intervals 
 Low-Medium [0.11] 0.58 (0.3 – 1.14) 
High-Medium [0.23] 0.67 (0.34 – 1.29) 





The graphs below show the disease free survival plotted against cytoplasmic 
expression of hENT1 for all pancreatic cancer patients in this cohort.  Some of these 
patients would have received chemotherapeutic intervention and some would have no 
treatment.  The analysis was run using TMA Navigator, a statistical programme which 
automatically divides the cohort into three equal groups.  The TMAs were constructed 
in quadruplicate – the data from all four TMAs was used for combat analysis and the 
median value of the 4 TMAs was used for the median analysis.  These two analyses 
were undertaken to see if the two methods of analysis produced conflicting results.  
The expression, or AQUA score, is determined by the pixel intensity (or fluorescence) 
of the target protein in the cytoplasm or nucleus (or both).  This value is normalised by 
calculating the total tumour area and light exposure time.104  If the total tumour area is 
less than 5% of the total area of the spot then it is automatically excluded from 
analysis.   
Comparing the graphs, the low and medium expression groups have almost identical 
times to disease progression when compared with the high expression group.  The 
median and combat values are very similar with the high expression group in both 
graphs having a slightly longer time to disease progression than the low and medium 
expression groups.  The p values are 0.35 and 0.5 for median values and combat 






Figure 3.18 Kaplan-Meier (tertile) plots of pancreatic cancer TMA hENT1 cytoplasm 
expression showing proportion of group against overall survival in months (median values 




Median values Combat data 
  











1(25) 77.33 - 186.96 142.01 1 87.89 - 187.82 141.75 
2(24) 187.82 - 251.22 229.68 2 191.55 - 254.57 226.27 
3(24) 254.57 - 1254.99 475.33 3 254.90 - 1625.25 451.38 
[P value] odds ratio and 95% confidence 
intervals 
 Low-Medium [0.54] 0.78 (0.36 – 1.69) 
High-Medium [0.33] 0.68 (0.31 – 1.47) 






3.6.2 Kaplan-Meier survival plots of patients who received 
gemcitabine pancreatic cancer TMA set 
The graphs below show the overall survival plotted against cytoplasmic expression of 
hENT1 for all pancreatic cancer patients who received gemcitabine.  The analysis was 
run using TMA Navigator, a statistical programme which automatically divides the 
cohort into three equal groups.  The TMAs were constructed in quadruplicate – the 
data from all four TMAs was used for combat analysis and the median value of the 4 
TMAs was used for the median analysis.  These two analyses were undertaken to see if 
the two methods of analysis produced conflicting results.  The expression, or AQUA 
score, is determined by the pixel intensity (or fluorescence) of the target protein in the 
cytoplasm or nucleus (or both).  This value is normalised by calculating the total 
Figure 3.19 Kaplan-Meier (tertile) plots of pancreatic cancer TMA hENT1 cytoplasm 
expression showing proportion of group against disease free survival in months (median 




tumour area and light exposure time.104  If the total tumour area is less than 5% of the 
total area of the spot then it is automatically excluded from analysis. 
The medium and high expression groups are similar in both graphs and the low 
expression groups fare best with the last patient surviving 67 months. 
This is a direct contradiction to our hypothesis which predicts that high hENT1 levels 
are indicative of gemcitabine sensitivity. The p values are 0.29 and 0.2 for median 










Median values Combat data 
  







Group  Expression 
Median 
value 
1 93.80 – 198.11 184.83 1(8) 93.80 - 197.02 169.23 
2 198.42 – 235.22 214.56 2(7) 198.11 - 229.59 218.41 
3 236.32 - 563.56 252.39 3(7) 230.71 - 1625.25 276.40 
[P value] odds ratio and 95% confidence 
intervals 
 Low-Medium [0.83] 1.17 (0.28 – 4.98) 
High-Medium [0.31] 0.48 (0.11 – 1.98) 
Low-High [0.36] 0.56 (0.16 – 1.94) 
Figure 3.20 Kaplan-Meier (tertile) plots of pancreatic cancer TMA hENT1 cytoplasm 
expression showing proportion of group against overall survival in months (median values 




The graphs below show the disease free survival plotted against cytoplasmic 
expression of hENT1 for all pancreatic cancer patients who received gemcitabine.  The 
analysis was run using TMA Navigator, a statistical programme which automatically 
divides the cohort into three equal groups.  The TMAs were constructed in 
quadruplicate – the data from all four TMAs was used for combat analysis and the 
median value of the 4 TMAs was used for the median analysis.  These two analyses 
were undertaken to see if the two methods of analysis produced conflicting results.  
The expression, or AQUA score, is determined by the pixel intensity (or fluorescence) 
of the target protein in the cytoplasm or nucleus (or both).  This value is normalised by 
calculating the total tumour area and light exposure time.104  If the total tumour area is 
less than 5% of the total area of the spot then it is automatically excluded from 
analysis. 
The median values graph shows separation of the groups with the low expression 
group taking the longest time to disease progression, however the p value is 0.17. 
The combat values graph shows the 3 expression groups are almost identical with the 
low expression taking the longest time to disease progression, however this isn’t 
statistically significant with a p value of 0.62. 
This is a direct contradiction to our hypothesis which predicts that high hENT1 levels 
are indicative of longer survival.  
 
Median values Combat data 
  
 p = 0.17 
 







Group  Expression 
Median 
value 
1 118.30 – 199.45 185.10 1(8) 93.80 - 197.02 169.23 
2 200.00  - 235.22 228.16 2(7) 198.11 - 229.59 218.41 




[P value] odds ratio and 95% confidence 
intervals 
 Low-Medium [0.5] 0.54 (0.09 – 3.28) 
High-Medium [0.23] 2.49 (0.56 – 10.96) 





3.6.3 Kaplan-Meier survival plots of patients who had no 
chemotherapy pancreatic cancer TMA set 
The graphs below show the overall survival plotted against cytoplasmic expression of 
hENT1 for all pancreatic cancer patients who did not receive chemotherapy.  The 
analysis was run using TMA Navigator, a statistical programme which automatically 
divides the cohort into three equal groups.  The TMAs were constructed in 
quadruplicate – the data from all four TMAs was used for combat analysis and the 
median value of the 4 TMAs was used for the median analysis.  These two analyses 
were undertaken to see if the two methods of analysis produced conflicting results.  
The expression, or AQUA score, is determined by the pixel intensity (or fluorescence) 
of the target protein in the cytoplasm or nucleus (or both).  This value is normalised by 
calculating the total tumour area and light exposure time.104  If the total tumour area is 
less than 5% of the total area of the spot then it is automatically excluded from 
analysis. 
In the median values graph the medium and high expression groups have a longest 
survival time of 16 and 18 months respectively.  The low expression group fared best 
with the longest survival time of greater than 48 months. 
In the combat values graph the high and low expression groups have a longest survival 
time of 18 and 44 months.  The medium expression group has a longest survival time 
of more than 48 months.  The p values are 0.13 and 0.47 for median values and 








Figure 3.21 Kaplan-Meier (tertile) plots of pancreatic cancer TMA hENT1 cytoplasm 
expression showing proportion of group against disease free survival in months (median 








The graphs below show the disease free survival plotted against cytoplasmic 
expression of hENT1 for all pancreatic cancer patients who did not receive 
chemotherapy.  The analysis was run using TMA Navigator, a statistical programme 
which automatically divides the cohort into three equal groups.  The TMAs were 
constructed in quadruplicate – the data from all four TMAs was used for combat 
analysis and the median value of the 4 TMAs was used for the median analysis.  These 
two analyses were undertaken to see if the two methods of analysis produced 
conflicting results.  The expression, or AQUA score, is determined by the pixel intensity 
(or fluorescence) of the target protein in the cytoplasm or nucleus (or both).  This 
value is normalised by calculating the total tumour area and light exposure time.104  If 
the total tumour area is less than 5% of the total area of the spot then it is 
automatically excluded from analysis. 
Median values Combat data 
  
 p = 0.13  p = 0.47 







Group  Expression 
Median 
value 
1 138.52 - 220.35 191.55 1(6) 131.30 - 191.55 154.80 
2 231.27 - 244.84 236.68 2(5) 206.09 - 258.59 244.84 
3 254.57 - 1020.48 340.65 3(5) 261.81 - 1088.83 334.67 
[P value] odds ratio and 95% confidence 
intervals 
 Low-Medium [0.26] 0.49 (0.15 – 1.69) 
High-Medium [0.37] 0.59 (0.18 – 1.87) 
Low-High [0.79] 0.85 (0.25 – 2.82) 
Figure 3.22 Kaplan-Meier (tertile) plots of pancreatic cancer TMA hENT1 cytoplasm 
expression showing proportion of group against overall survival in months (median values 




In the median values graph the low expression groups has the shortest time to disease 
progression – 8 months.  The medium and high expression groups both have 
approximately 20% of the group progression free at 30 months.  This is not statistically 
significant with a p value of 0.09.   
The combat values graph shows the low and high expression groups with near 
identical lines with 20% of both groups progression free at 24 months.  The medium 
expression group has 35% of patients progression free at 30 months.  The combat 








Median values Combat data 
  
Median values Combat data 






Group  Expression 
Median 
value 
1(7) 138.52 - 220.35 191.55 1(6) 131.30 -  191.55 154.80 
2(6) 231.27 - 244.84 236.68 2(5) 206.09 - 258.59 244.84 
3(6) 254.57 - 1020.48 340.65 3(5) 261.81 - 1088.83 334.67 
[P value] odds ratio and 95% confidence 
intervals 
 
 Low-Medium [0.16] 0.42 (0.12 – 1.43) 
High-Medium [0.27] 0.52 (0.16 – 1.65) 
Low-High [0.73] 0.81 (0.24 – 2.69) 
Figure 3.23 Kaplan-Meier (tertile) plots of pancreatic cancer TMA hENT1 cytoplasm 
expression showing proportion of group against disease free survival in months (median 




3.7 Colorectal cancer TMA set results 
All graphs can be seen in Appendix 22. 
The graphs show analysis of the 5 proteins involved in the metabolism of 5-FU to its 
active state – TP, DPYD, TS, RRM1 and RRM2.  The cohort was divided into Dukes A/B 
and Dukes C/D.   
The Kaplan Meier survival graphs show the overall and disease free survival for  
a) All colorectal cancer patients regardless of whether or not they received treatment. 
b) Patients who received 5-FU. 
c) Patients who did not receive chemotherapy. 
 
3.7.1 Kaplan-Meier survival plots colorectal cancer TMA set of all 
patients 
The only significant result is DPYD in the Dukes C/D cohort.  Low expression levels of 
DPYD (in Dukes C/D) are linked to longer overall and disease free survival, the p 
values are 0.03 and 0.07 for the survival types respectively.  What is interesting about 
this result is that the AQUA expression levels range from 31.28 to 84.96.  If 
conventional IHC had been used on these sections they would have been scored 
negative.  However, it would appear that even extremely low scoring is important 
clinically with regards to DPYD.  
  
Overall survival Dukes C/D cytoplasmic expression of DPYD 
Median values Combat data 
  
 p = 0.36  p = 0.03 
Group  Expression Median value 
Group  
(n=21) 
Expression Median value 
1 (21) 31.28 - 37.48 34.30 1  32.14 - 38.37 36.80 
2 (20) 37.72 - 43.14 40.87 2  39.02 - 44.14 41.76 
3 (21) 43.60 - 84.96 46.69 3  44.16 - 84.96 46.99 
 
 
Figure 3.24 Kaplan-Meier (tertile) plots of Dukes C/D colorectal cancer TMA DPYD 
cytoplasm expression showing proportion of group against overall survival in months (median 





Disease free survival Dukes C/D cytoplasmic expression of DPYD 
 
Median values Combat data 
  
 p = 0.61  p = 0.07 
Group  Expression Median value 
Group  
(n=21) 
Expression Median value 
1 (21) 31.28 - 37.48 34.30 1  32.14 - 38.37 36.80 
2 (20) 37.72 - 43.14 40.87 2  39.02 - 44.14 41.76 





3.7.2 Kaplan-Meier survival plots colorectal cancer TMA set of all 
patients who received 5-FU  
All graphs can be seen in Appendix 22. 
The Kaplan Meier survival graphs below show the overall and disease free survival for 
all colorectal cancer patients who received 5-FU either singly or as a combination 
therapy. 
The only significant result is DPYD in the Dukes C/D cohort.  Low expression levels of 
DPYD (in Dukes C/D) are linked to longer overall survival, the p value is 0.029.  What 
is interesting about this result is that the AQUA expression levels range from 32.14 to 
47.54.  If conventional IHC had been used on these sections they would have been 
scored negative.  However, it would appear that even extremely low scoring is 




Figure 3.25 Kaplan-Meier (tertile) plots of Dukes C/D colorectal cancer TMA DPYD 
cytoplasm expression showing proportion of group against disease free survival in months 








3.7.3 Kaplan-Meier survival plots colorectal cancer TMA set of all 
patients who did not receive chemotherapy 
All graphs can be seen in Appendix 22.  There are no statistically significant results for 












Median values Combat data 
  
 p = 0.45  p = 0.029 
Group  
(n=12) 
Expression Median value Group  Expression Median value 
1  31.35 - 37.48 34.25 1 (10) 32.14 - 39.02 36.58 
2  39.02 - 42.94 41.00 2 (9) 39.50 - 44.14 41.76 
3  43.14 - 53.92 48.16 3 (10) 44.29 - 57.70 47.54 
Figure 3.26 Kaplan-Meier (tertile) plots of Dukes C/D colorectal cancer TMA DPYD 
cytoplasm expression showing proportion of group against overall survival in months (median 





3.8 Colorectal cancer primary and matched liver metastases 
results 
The pictures below show a primary colorectal tumour on the left with the liver 
metastasis on the right.  The proteins shown are linked with gemcitabine metabolism – 
hENT1, DCK, RRM1 and RRM2 – and also those linked with 5-FU metabolism – TS, TP, 





Colorectal primary TP Liver TP 







Colorectal primary DPYD Liver DPYD 
Colorectal primary RRM2 Liver RRM2 










Colorectal primary hENT1 Liver hENT1 
Colorectal primary RRM1 Liver RRM1 
Colorectal primary DCK Liver DCK 
Figure 3.27 Matched colorectal cancer primary tumour on the left and matched liver 
metastasis on the right showing the change in protein expression that may occur during 






Statistical analysis of this TMA set of patients showed that the protein RRM2 was 
important in all patient groups.  The results below show the overall survival results for 
all patients RRM2 cytoplasm expression.  The analysis was run using TMA Navigator, a 
statistical programme which automatically divides the cohort into three equal groups.  
The TMAs were constructed in quadruplicate – the data from all four TMAs was used 
for combat analysis and the median value of the 4 TMAs was used for the median 
analysis.  These two analyses were undertaken to see if the two methods of analysis 
produced conflicting results.  The expression, or AQUA score, is determined by the 
pixel intensity (or fluorescence) of the target protein in the cytoplasm or nucleus (or 
both).  This value is normalised by calculating the total tumour area and light exposure 








Median values Combat data 
  
 p = 0.026  p = 0.038 
Group  
(n=26) 
Expression Median value Group  Expression Median value 
1  1023.24 - 2072.37 1587.65 1 (27) 105.96 - 2037.72 1568.19 
2  2073.89 - 3111.38 2406.80 2 (26) 2073.89 - 3445.94 2524.08 
3  3247.30 - 12468.20 4277.32 3 (26) 3717.51 - 12468.20 4800.11 
Figure 3.28 Kaplan-Meier (tertile) plots of colorectal primary cancer TMA RRM2 cytoplasm 
expression showing proportion of group against overall survival in months (median values 




The results below show the overall and disease free survival results for all patients who 
received 5-FU RRM2 cytoplasm expression.  The analysis was run using TMA Navigator, 
a statistical programme which automatically divides the cohort into three equal groups.  
The TMAs were constructed in quadruplicate – the data from all four TMAs was used 
for combat analysis and the median value of the 4 TMAs was used for the median 
analysis.  These two analyses were undertaken to see if the two methods of analysis 
produced conflicting results.  The expression, or AQUA score, is determined by the 
pixel intensity (or fluorescence) of the target protein in the cytoplasm or nucleus (or 
both).  This value is normalised by calculating the total tumour area and light exposure 
time.104   
High RRM2 expression is linked to longer overall survival and surprisingly, medium and 









Median values Combat data 
  











1  105.96 - 1728.37 1376.24 1  105.96 - 1913.75 1467.90 
2  2073.89 - 3445.94 2577.97 2  2037.72 - 3445.94 2577.97 
3  3495.84 - 12468.20 4283.77 3  3717.51 - 12468.20 4653.50 
Figure 3.29 Kaplan-Meier (tertile) plots of colorectal primary cancer TMA RRM2 cytoplasm 
expression showing proportion of group against overall survival in months (median values 








There are no statistically significant results for the cohort of colorectal cancer primary 
patients who did not receive chemotherapy in this TMA set.  
It is very interesting that RRM2 cytoplasm expression in the liver secondary tumour 
TMA sets are all statistically insignificant.  
 
The graph below was generated using the statistical function in excel and shows the 
change in cytoplasm RRM2 expression from primary tumour to secondary.  Expression 
not only changes from high to low but also low to high. 
Median values Combat data 
  











1  105.96 - 1728.37 1376.24 1  105.96 - 1913.75 1467.90 
2  2073.89 - 3445.94 2577.97 2  2037.72 - 3445.94 2577.97 
3  3495.84 - 12468.20 4283.77 3  3717.51 - 12468.20  4653.50 
Figure 3.30 Kaplan-Meier (tertile) plots of colorectal primary cancer TMA RRM2 cytoplasm 
expression showing proportion of group against disease free survival in months (median 











Figure 3.31 Graph showing the change in RRM2 cytoplasm expression in colorectal cancer 
primary tumour on the left hand side to the matched liver metastatic tumour on the right 
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3.9 Discussion  
Quality 
A quality management system was implemented for this research study to examine whether 
doing so actually contributed to or altered the final results in any way.  The quality results 
are arguably more important than the biological results, as they could potentially impact on 
every single MSc and PhD project, as well as all academic research.  Below is a list of quality 
steps and outcomes: 
 The TMA map was reconciled against the blocks and slides.  One error was found 
during this check and the block and slide discarded.   
 TMA sections were checked by Professor Harrison to exclude any that contained no 
cancer.  If these had been included in the final analysis it is highly probable that this 
would have generated different results. 
 TMA sections were cut and stored at what is believed to be the optimum conditions.  
This was checked and validated by storing sections at different temperatures and 
comparing. 
 An attempt was made to validate the antibodies available to researchers.  This 
highlighted the variation in quality of antibodies and showed that it is a game of 
chance when purchasing antibodies.   
 AQUA analysis was performed using two separate pieces of equipment.  The results 
from both were quality checked and it was found the results were consistent across 
both machines. 
 All data collected and analysed was QC checked.  Some transcription errors were found 
and these were corrected before the final QA audit.  Has these errors been missed it 
is possible that the results generated would be different. 
  The final QA audit reconciled results against source data to ensure that what was 
reported was what was generated.  The only reason this was error free was because 
of the QC checking implemented.  If no quality checks were undertaken the final 
biological results may have turned out completely different.   
The final results of this project would have been considerably different if the QA/QA checks 
were not implemented.  If the TMA map had not been reconciled then the wrong results 
would have been recorded which alone may not have impacted hugely on the results.  
However, add to this the fact that the TMA cores were checked by an expert and non-





It is of paramount importance to QC check any results wherever possible and this was 
included in this project.  If the errors found had not been corrected then the results would 
have been different. 
If time and word count had permitted, it would have been extremely enlightening to conduct 
two arms to this project in parallel – implementing quality in one arm and omitting quality in 
the other.  This would entail double the results presented however, it would be conclusive 
evidence that quality should be included in all research, no matter the size of the project. 
 
Pancreatic cancer 
Pancreatic cancer is one of the most challenging solid tumours to treat, mainly due to the 
fact that less than 20% of patients present with resectable tumours as a direct consequence 
of the fact that pancreatic cancer is symptom-free in the early stages or symptoms mimic 
other diseases.53 96  Pancreatic cancer patients with unresectable, metastatic disease have an 
average survival time of 2-6 months.  Because time is so limited in this patient cohort there 
is an urgent need to stratify patients to tailored therapy that will increase survival time.  It is 
also important that these patients, who have such a limited life span, are not subjected to 
chemotherapeutic treatments of which the side-effect:benefit ratio renders it pointless. 
 
As described in chapter 2, automated quantitative analysis system AQUA was utilised to 
quantify potential prognostic and predictive biomarkers.  These were then analysed both 
singly and in combination. 
 
Univariate analysis 
1. The complete patient set was evaluated for OS and DFS to see if any single protein 
expression showed a prognostic value.  Low CDA expression and low RRM1 
expression were associated with longer DFS in the complete set of patients with 
borderline statistical significance (p=0.06).  There was nothing significant in OS for 
this group.  
2. The group of patients who received gemcitabine was evaluated for OS and DFS.  Low 
RRM1 expression corresponded with longer overall and disease free survival (p=0.02 
and p=0.04 respectively). 
3. The group of patients who didn’t receive any chemotherapy was evaluated for OS and 
DFS.  This was to check whether the results generated by the group that received 
gemcitabine were specific to this group or whether this was an effect being seen 
across both groups.  In the group of patients who received no chemotherapy, there 






DCK is responsible for the phosphorylation of gemcitabine to gemcitabine monophosphate.  
RRM1 and RRM2 are responsible for catalysing the biosynthesis of deoxyribonucleotides from 
the corresponding ribonucleotides.  Thus it is reasonable to hypothesise that increased 
survival time could be associated with high DCK and low RRM1/ RRM2 expression. 
Lecca et al described an algorithmic model of gemcitabine activity involving DCK, RRM1 and 
RRM2.
128
  A final equation was created using DCK, RRM1 and RRM2 - DCK/(RRM1*RRM2) – 
and this equation was used as a means of multivariate analysis.  
1. The complete patient set was analysed for OS and DFS; there was no difference in 
survival between the different expression groups.  
2. The group of patients who received gemcitabine was evaluated for OS and DFS; a 
high Lecca value was linked to increased OS and DFS (p = 0.007 and p = 0.07 
respectively).  Taken at face value, this would suggest that a high Lecca value could 
potentially be a predictive biomarker for gemcitabine. 
3. The group of patients who didn’t receive chemotherapy was analysed for OS and DFS.  
This group showed the same stratification of expression groups as patients who 
received gemcitabine. That is, the high expression group showed longer OS and DFS.  
Analysing this group of patients has shown that increased OS and DFS is not 
specifically linked to the gemcitabine group, but also seen in the group that didn’t 
receive chemotherapy.   
 
Comparing the gemcitabine group with the no chemotherapy group; at 30 months (high 
expression group) 26% of patients who received no chemotherapy and 43% of patients who 
received gemcitabine were progression free.  
24% of patients who received no chemotherapy (high expression group) were still alive at 48 
months and 25% of patients who received gemcitabine (high expression group) were still 
alive at 72 months.  Both the gemcitabine and untreated groups show the same high 
expression trend however, the gemcitabine group showed longer survival in the high 
expression group. 
In the low expression groups, both sets of patients had the same amount of time to disease 
progression, 14 months.  This would indicate that the Lecca formula may be useful in 
randomising patients not to receive gemcitabine and that offering the drug to patients with a 





hENT1 is considered an independent predictor of gemcitabine resistance as it is one of the 
main proteins involved in transport into the cell.  Transport of gemcitabine across the 
membrane is essential however there are several transporters capable of this - SLC28 
transporters are sodium-dependent concentrative nucleoside transporters (CNTs), whereas 
the SLC29 transporters are sodium-independent equilibrative nucleoside transporters (ENTs) 
and consist of SLC29A1, SLC28A1, and SLC28A3.130 It is important to take into account the 
subcellular location of hENT1 – if it is not localised to the cell membrane then no matter how 
great the amount of hENT1, it would not facilitate the transport of gemcitabine across the 
cell membrane if retained within the cell. 131  hENT1 expression effects on survival in this 
project were not conclusive. 
 
It could be argued that biomarker research should be conducted via prospective clinical 
trials.  Using retrospective FFPE samples is a relatively simple way to perform rapid analyses.  
The downside to this is the patient numbers tend to be low when the research is conducted 
as a single site, and the lack of robust negative controls or disregard of untreated group 
results could lead to incorrect interpretation of data.135 136    One way to counteract this 
would be to conduct biomarker research via a multi-centre study: this would ensure that the 
study is powered adequately and ensure that a control or placebo group is in place.   
One clinical trial compared gemcitabine with FOLFIRINOX (oxaliplatin, irinotecan, 
fluorouracil, and leucovorin) therapy in patients with metastatic pancreatic cancer, with 
response rates of 9.4% and 31.6% respectively. 132 133  
These response rates reinforce the necessity of further research into drug resistance.  They 
also highlight the fact that there must be some other underlying reason why patients do not 
respond to gemcitabine therapy; it is not as straightforward as using protein biomarkers to 
predict response.  The mechanisms involved in gemcitabine metabolism have been 
documented for many years, yet there remains no definitive answer mainly due to conflicting 
results and inadequate sample size. 95  
 
More research is required into the mechanisms of drug resistance, for example the signalling 
pathways which regulate the cell cycle and apoptosis.  One research group found that the 
level of MAPK/ERK pathway activation correlates with sensitivity to gemcitabine.134 These 
pathways may be targets for drugs which could assist in gemcitabine sensitivity however, 
targeting one pathway can result in disruption to another pathway rendering the subject of 
drug resistance both dynamic and very complex.  
Other researchers have looked at tumour associated macrophages (TAMs) and found that 




resistance to gemcitabine, so it is possible that cancer cells are only part of the determinant 
of ultimate outcome after therapy. 135 136 
 
Colorectal cancer 
The colorectal cancer TMA set showed that the cytoplasmic expression of DPYD was 
statistically significant.  Low expression was linked to longer overall survival in the cohort of 
all patients and longer overall and disease free survival in the Dukes C/D cohort of patients 
who received 5-FU.  There were no significant findings in the cohort of patients who did not 
receive chemotherapy. 
What is really interesting about these results is the fact that the AQUA expression levels 
were extremely low.  If the staining had been done as routine clinical IHC then all the 
sections would have been scored negative.  Perhaps this result should be held up as a 
reason to routinely stain using IF for AQUA analysis instead of IHC? 
 The colorectal primary cancer TMA set results are also interesting.  It would not be 
inconceivable to expect this patient cohort to have a similar result to the colorectal cancer 
Dukes C/D cohort.  Instead the cytoplasmic expression of RRM2 is statistically significant.  
High expression was linked to longer overall survival in the cohort of all patients and longer 
overall and disease free survival in the patient group that received 5-FU.  There were no 
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